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ABSTRACT OF DISSERTATION

INVOLVEMENT OF THE RENIN ANGIOTENSIN SYSTEM IN MARFAN
SYNDROME ASSOCIATED THORACIC AORTIC ANEURYSMS
Thoracic aortic aneurysms (TAAs) are clinically-silent dilations of the aorta
which greatly increase the risk of aortic rupture, a condition with 50-90% mortality.
Marfan syndrome (MFS) is caused by mutations in fibrillin-1 (FBN1) and is
associated with TAAs. Due to an absence of validated and effective pharmacologic
therapies to prevent or reverse TAA, most MFS patients require surgical aortic
repair. Understanding MFS associated TAA pathogenesis would direct
development of new pharmacologic therapies. Previous research has implicated
the renin angiotensin system in TAA. In both males and females, angiotensinogen
(AGT) is cleaved serially to generate the main effector peptide angiotensin II
(AngII). AngII is the main ligand of AngII receptor type 1a (AT1aR). However, the
role of angiotensin II (AngII) receptor type 1a (AT1aR) in MFS associated TAA
formation is unclear. Here, we test the hypothesis that AngII-dependent AT1aR
stimulation is responsible for Marfan syndrome associated TAA.
To study the contribution of the renin angiotensin system on MFS
associated TAA, we used the fibrillin-1 haploinsufficient (Fbn1C1041G/+) and
fibrillin-1 hypomorphic (Fbn1mgR/mgR) mouse models. TAA in MFS mice
demonstrated sexual dimorphism. Compared to male Fbn1C1041G/+ mice,
female Fbn1C1041G/+ mice exhibited less ascending aortic dilation. To study
AT1aR in MFS associated TAA, we bred male and female AT1aR deficient
(AT1aR-/-) x Fbn1C1041G/+ mice. We measured the ascending aorta up to 12
months of age by high frequency ultrasound sequentially. We evaluated aortic
medial structure at study termination. Compared to male AT1aR+/+ x
Fbn1C1041G/+ mice, male AT1aR-/- x Fbn1C1041G/+ mice exhibited less
ascending aortic dilation and reduced elastin fragmentation. Ascending aortic
dilation was not significant between female AT1aR-/- x Fbn1C1041G/+ mice and
female AT1aR+/+ x Fbn1C1041G/+ mice. To study the contribution of angiotensin
peptides, we administered angiotensinogen antisense oligonucleotides (AGT
ASO) to male Fbn1C1041G/+ mice. Compared to male Fbn1C1041G/+ mice

administered control ASO, mice administered AGT ASO exhibited less ascending
aortic dilation and reduced elastin fragmentation.
TAA in the mouse models of MFS is sexually dimorphic. Inhibition of the
renin angiotensin system via either AT1aR deletion or AGT ASO is sufficient to
attenuate ascending aortic dilation in male Fbn1C1041G/+ mice. However, the
effect of AT1aR deletion was not detectable in female Fbn1C1041G/+ mice.
Depletion of angiotensin ligands was efficacious in attenuating MFS associated
TAA in male Fbn1C1041G/+ mice. However, factors that impact TAA of other
etiologies have minimal impact on MFS associated TAA. These studies indicate
that modulating the renin angiotensin system is highly effective to attenuate MFS
associated TAA in males.
KEYWORDS: Marfan syndrome, Thoracic Aortic Aneurysm, Renin Angiotensin
System, Angiotensin II
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CHAPTER 1. INTRODUCTION
1.1

Marfan syndrome

Marfan syndrome (MFS) is an autosomal dominant genetic disease
caused by mutations in a large extracellular matrix protein, fibrillin-1 (FBN1). (1) It
has an incidence of approximately 1:3000 live births and is associated with
increased morbidity and mortality for a significant number of affected patients. As
a syndromic disorder, Marfan syndrome is characterized by a constellation of
features that forms the basis of diagnosis. Thoracic aortic aneurysms (TAAs) are
a key feature in Marfan syndrome that drives both diagnosis and prognosis. This
section will review the common clinical features seen in Marfan syndrome, the
fibrillin-1 gene and protein, and Marfan syndrome mouse models.
Clinical features of Marfan syndrome include dysmorphic features, ectopia
lentis, and thoracic aortic aneurysms. Alongside genetic testing for pathologic
mutations in the FBN1 gene and family history of Marfan syndrome, these form
the basis of the 2010 Revised Ghent Nosology. (2) Dysmorphic features are
tabulated as a systemic score. Characteristic features include hypermobility,
skeletal deformations, skin features, and specific cardiopulmonary conditions.
Another key phenotype is the presence of detached lenses in the eye or ectopia
lentis. Evaluation of this feature requires an ophthalmologist. However, the most
important criteria is the presence of aortic root dilation. Specifically, if the aortic zscore (aortic root diameter normalized to body surface area) is greater than 2,
only one additional of the above criteria is needed to make a definitive diagnosis
of Marfan syndrome in patients without a family history. In patients with a positive
family history of Marfan syndrome or known pathologic FBN1 mutation, aortic
dilation alone is enough to make the diagnosis of Marfan syndrome. Male
patients with Marfan syndrome develop more severe aortic dilation compared to
female counterparts. (3-5) Because Marfan syndrome is inherited in an
autosomal dominant fashion, it is unclear why this sexual dimorphism exists.
Thoracic aortic aneurysm by itself is clinically silent and often asymptomatic.
However, it is associated with an increased risk of aortic rupture and dissection
due to loss of aortic wall integrity. This topic will be reviewed in a later section.
Although Marfan syndrome is a systemic disease that affects multiple organ
systems, TAA remains the leading cause of morbidity and mortality in patients
with Marfan syndrome.
Fibrillin-1 mutations form the basis of Marfan syndrome, a disorder
characterized by connective tissue abnormalities and thoracic aortic
aneurysms.(6) Aortic tissues from patients with Marfan syndrome display
extensive elastin fragmentation (7) and strikingly decreased mature elastin - as
detected by desmosine extraction - without changes in collagen content.(8)
Fibrillin-1 is one of the most well characterized microfibrillar proteins in the
context of aortic elastin stability. Members of the fibrillin protein family are found
in elastic connective tissue where they serve as a critical component of the
microfibrillar scaffold. In general, fibrillins are comprised of an identifying Nterminal domain that distinguishes FBN1 from FBN2, structural calcium binding

epidermal growth factor domains and proline/glycine domains that provide
flexibility and rigidity, and tumor growth factor β (TGFβ) binding domains that
anchor cell-signaling elements. Other notable binding partners include growth
factors, structure proteins (elastin and fibulins), as well as cells through integrin
binding. (9, 10) (Table 1.1) Mutations in fibrilin-1 affect elastic tissue integrity by
disrupting these interactions.
Based on mutations in FBN1, several mouse models of Marfan syndrome
have been developed to mimic the human disease. These mouse models display
progressive aortic dilation of varying severity. The fibrillin-1 haploinsufficient
(Fbn1C1041G/+) mouse model is based on a single nucleotide substitution that
causes a missense mutation. This mouse model mimics the human FBN1C1039Y
mutation, which impacts a calcium binding epidermal growth factor-like domain of
fibrillin-1. (11) Fbn1C1041G/+ mice develop TAA over the course of 6 months. Our
data indicates that aortic dilation can be detected as early as 1 month of age.
The fibrillin-1 hypomorphic (Fbn1mgR/mgR) mouse model is a severe model of
Marfan syndrome. (12) This mutation incorporates a targeting vector between
exon 18 and 19. While native fibrillin-1 is expressed, protein levels are greatly
diminished. These mice develop aggressive TAA and often die of aortic rupture.
Our observations in this mouse model confirm that the median lifespan is
approximately 3 months of age. Additionally, these mice develop dilated
cardiomyopathy. The FBN1GT-8 mouse model expresses a green fluorescence
protein tagged, truncated fibrillin-1. (13) These mice also develop TAA and
extensive elastin fragmentation. Deletion of FBN1 is embryonic lethal while
deletion of one copy induces TAA. (14) In summary disruption of either the
structure or normal abundance of fibrillin-1 results in TAA of varying severity.
Marfan syndrome was first described in 1896 and FBN1 was first linked to
Marfan syndrome over 30 years ago, yet current therapies have not been shown
to reverse TAA. Therefore, there is great need to investigate not only
pathophysiology of Marfan syndrome associated TAA but also new therapies for
this disease.
1.2

Structure of the Thoracic Aortic Media

The aorta is composed of three discrete layers: the intima, the media, and
the adventitia. Of these, the aortic media occupies the majority of the aortic wall
and is composed of vascular smooth muscle cells and elastin. In this section, we
will outline the key characteristics of the major cellular and extracelluar
components in the aortic media.
Vascular smooth muscle cells found in the aortic media provide structural
stability to the thoracic aorta. These cells are derived from the second heart field
and cardiac neural crest. Second heart field derived cells traced with the Mef2c
promoter driven cre were found closer to the aortic root. Cardiac neural crest
cells traced with the Wnt1 promoter driven cre were found up to the ligamentum
arteriosum. (15, 16) Within the ascending aorta, second heart field derived cells
occupy the outer aortic media and cardiac neural crest traced cells occupy the
inner media. (16) While the functional importance of these embryologic origins is
11

unknown, lineage traced cells correlate closely with pathological remodeling in
aortopathy. Aortopathies often involve remodeling of the outer aortic media. This
includes elastin fragmentation and medial hemorrhage. (17) Smooth muscle cells
are also the source of aortic extracellular matrix proteins. In fact, genetic
depletion of the gene encoding tropoelastin in vascular smooth muscle cells
results in extensive loss of elastin. (18) interestingly, loss of elastin results in
pathologic proliferation of smooth muscle cells and obstructive aortic disease
(19-22) Thus vascular smooth muscle cells influence and are influenced by
extracellular matrix of the aortic media.
Within the media, elastic fibers approximately 0.1µm thick are organized
into discrete lamellar layers. The process of elastin fiber synthesis is highly
orchestrated and requires multiple players. Elastin fiber synthesis requires
formation of a microfibrillar complex composed of tropoelastin, fibrillins, fibulins,
and EMILINs. Mutations and deficiencies of these components generally result in
aortopathy. (Table 1.2) Elastin is more abundant in the ascending aorta and
aortic arch compared to the descending and abdominal aorta. (23, 24). In
humans, the thoracic aorta is comprised of up to 60 elastin layers, whereas the
descending and abdominal aorta consists of about 30 or less discrete elastin
lamina -- with a corresponding decrease in aortic wall thickness.(24-26) The
decrease in layers and thickness is also associated with a decrease in the
amount of elastin from the proximal to the distal aorta.(27) This feature is also
seen in smaller animals. In mice, the ascending and arch regions consists of
about 8-12 lamellar units, while the abdominal aorta consists of 3-5 lamellar
units. (28) Likewise, comparative physiology studies revealed the number of
aortic elastic lamella are directly and linearly proportional to aortic diameters. (25)
Recent studies have indicated that the origins of elastic lamina are
heterogenous. While smooth muscle cells generate the majority of elastin in the
media, endothelial cells contribute to elastin in the internal elastic lamina. (18)
Within the aorta, elastic lamina resist the cyclic force of blood throughout the
cardiac cycle. The aorta slightly expands during systole, and this expansion is
necessary to maintain perfusion pressure during diastole through the Windkessel
effect. (29) By providing elasticity, elastin is a critical component to the structure
and function of the aorta. When elastin is disrupted, vascular malformations
occur. This suggests that the number of elastin lamina are adapted to cope with
stress and strain on aortic tissue but does not explain why aneurysmal disease
impacts the ascending and abdominal segments – the regions with the most and
the least number of elastin lamina – while sparing the intervening descending
segment.
The aortic media is made of a complex network of vascular smooth
muscle cells and extracellular matrix proteins. In Marfan syndrome, mutations in
fibrillin-1 are thought to disrupt these interactions. Disruption of these interactions
weakens the structural integrity of the aortic wall and results in aortopathy.
1.3

Thoracic Aortic Aneurysms
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Thoracic aortic aneurysms are expansions of the aortic lumen that weaken
the aortic wall and increase the risk of catastrophic failure. Tools and mouse
models developed to study and measure TAA must assay these disease features
and replicate common etiologies in order to develop effective medical therapies.
Aortic dilation and medial remodeling are two hallmarks of TAA. Thoracic aortic
aneurysms are clinically defined as greater than 150% expansion of the normal
aorta. This criterion is often not used in murine studies of the thoracic aorta
because there is no evidence of a bimodal distribution of responders/nonresponders unlike in the abdominal aorta. TAA is characterized by expansion of
the aortic lumen without separating layers of the aortic wall. Interestingly, TAA
can affect both the aortic root and ascending aorta by separate, distinct
mechanisms. (30, 31) TAAs of different etiologies give rise to a distinct pattern of
aneurysms involving regions of the thoracic aorta. Due to this regional
heterogeneity, standardization of measurements is important in order to make
equivalent comparisons. Although there is currently no published
recommendation in aortopathies, we may extrapolate suggestions from
atherosclerosis studies. Specifically, both the sex of mouse and region of aorta
analyzed should be similar across all groups. (32, 33) Thus standardization of
measurement is important, and will be covered in a later chapter. We have
developed and validated a protocol for the measurement of ascending aorta in
mice by ultrasound. This standardized protocol states that measurements should
be consistently imaged in diastole from the left parasternal view.(34) Additionally,
we have correlated these measurements with other indicators of TAA such as
elastin fragmentation. (35) Elastin fragmentation is a common feature of TAA.
(17) It is defined as breaks in the elastic lamina as detected by histology. Normal
aortic medial architecture displays continuous, concentric elastin layers.
Concentric lamina are fragmented in TAA. Although its etiology is unknown, it
may be caused by either malformation of elastic lamina or degradation of mature
elastic lamina. Both aortic dilation and loss of aortic integrity weaken the aortic
wall and increase risk of rupture or dissection. Ultimately, loss of normal aortic
architecture increases risk of dissection and rupture. Thus, it is important to
measure both the degree of aortic dilation and elastin fragmentation to determine
the overall severity of TAA.
1.4

Etiologies of Thoracic Aortic Aneurysms

TAA can occur spontaneously or in context of syndromic disease, both of
these etiologies are replicated in TAA mouse models. In humans, risk factors
such as smoking and hypertension increase the risk of spontaneous TAA. (36)
However, mouse models of spontaneous TAA, such as the AngII-infused, βAminopropionitrile induced, and deoxycorticosterone acetate and salt induced
TAA do not entirely mimic human disease. (37-39) While hypertension is seen in
the AngII and DOCA-salt models, TAA occurs independently of hypertension. In
fact, norepinephrine administered mice that develop increased systolic blood
pressure equivalent to AngII-infusion do not develop TAA. (17) Thus, the
mechanism by which spontaneous TAAs develop in both humans and mice is
13

unclear. TAA can also occur in context of syndromic disease. Fibrillin-1 mutations
form the basis of Marfan syndrome, a disorder also characterized by connective
tissue abnormalities and thoracic aortic aneurysms.(6) (6, 40) However,
mutations in genes that encode proteins which interact with fibrillin-1, such as
LOX and LTBP3, are also associated with syndromic TAA. (41, 42) Mutations in
the TGFβ pathway also lead to syndromic TAA and specific mutations are
defined as subtypes of Loeys-Dietz syndrome. (43, 44) Vascular Ehlers-Danlos
Syndrome is caused by mutations in COL3A1. (45) Finally, next generation
sequencing has elucidated several genes, such as FOXE3, ACTA2, and MYLK,
involved in familial TAA and dissection. (46-49) Several mouse models have
been developed to mimic human TAA. Although there are nuanced differences
between TAA mouse models, the majority display some degree of luminal
dilation and elastin fragmentation in the aortic media. (50) The Marfan syndrome
mouse models, specifically the fibrillin-1 haploinsufficiency (Fbn1C1041G/+) and
hypomorphic (Fbn1mgR/mgR) mouse models, display progressive aortic dilation of
varying severity. (11, 12, 51, 52) Mice with loss of function mutations affecting
TGFβ signaling develop TAA and dissections. (53-55) Ehlers-Danlos model mice
display aortic defects. (45) This area of research is rapidly expanding with the
ability to rapidly replicate human mutations in mice. Interestingly, most research
has used male mice only or have only studied sex differences in these models in
the context of pregnancy and nursing. (45, 56) Only one study in the Fbn1GT8/+
model of Marfan syndrome has shown sexual dimorphism in this context. (56)
Thus mouse models of both spontaneous and syndromic TAA are valuable tools
to study the pathogenesis of this disease.
1.5

Current Therapies for Thoracic Aortic Aneurysms

Currently, there is no proven medical therapy that reverses TAA. In
Marfan syndrome, both beta- adrenergic blockers and renin angiotensin system
inhibitors are used clinically. (57, 58) Despite widespread usage, evidence for the
efficacy of beta-blockers in attenuating or reversing TAA is lacking. (59) Similarly,
randomized control trials of losartan, an angiotensin receptor blocker, have
shown mixed results. Losartan is a short acting, surmountable AT1aR antagonist,
and may not be adequate to suppress the renin angiotensin system. Of the three
largest trails of losartan, COMPARE demonstrated that losartan was superior to
no additional treatment, the Pediatric Heart Network trial demonstrated no
difference between losartan and atenolol, and MARFAN SARTAN demonstrated
losartan added-on was not superior to placebo. (60-62) Conversely, the AIMS
trial demonstrated that use of an insurmountable AT1aR antagonist, irbesartan,
resulted in a reduction of the rate of aortic dilation.(63) These studies were based
on the observation that losartan attenuated TAA in a Marfan syndrome mouse
model. (64) The efficacy of irbesartan, an insurmountable agonist, holds further
promise that adequate and sustained inhibition of renin angiotensin system may
be efficacious. The mechanism by which these pharmacologic agents attenuate
TAA is not known. We will review the evidence for the involvement of the renin
14

angiotensin system in TAA in the next section. Conversely, several
pharmacologic agents have been shown to exacerbate TAA. One observational
study demonstrated that calcium channel blockers were associated with worse
outcomes in patients with Marfan syndrome. (65) Additionally, patients exposed
to fluoroquinolones, a common antibiotic, had increased risk for aortic rupture.
(66) The mechanism for these observations is unclear. Due to a lack of
understanding of TAA pathogenesis, there is a lack of effective medical therapies
to reverse TAA. In this dissertation, we will focus on syndromic TAA by
investigating the contribution of the renin angiotensin system to aortopathy in a
mouse model of Marfan syndrome. We not only describe validation of key
measurements that assay thoracic luminal dilation and elastin fragmentation but
also test the efficacy of a novel modality of renin angiotensin system inhibition in
attenuating Marfan syndrome associated TAA.
1.6

The Renin Angiotensin System in TAA

The renin angiotensin system is a key mediator of aortic homeostasis that
can be pharmacologically and genetically manipulated. These manipulations can
be leveraged to impact TAA, but the mechanism by which this occurs is
unknown. In this section, we will outline the ligand and receptor portions of the
renin angiotensin system, genetic and pharmacologic modulators of the renin
angiotensin system, and evidence for the involvement of the renin angiotensin
system in TAA.
The renin angiotensin system can be separated into a ligand portion and a
receptor portion. To generate angiotensin ligands, a series of enzymatic
cleavages process angiotensinogen into its main effector peptide, angiotensin II
(AngII). Angiotensinogen is the sole endogenous precursor to all angiotensin
peptides. It contains 452 amino acids that is mainly synthesized by the liver. (67)
Action of renin cleaves the 10 N-terminal residues to liberate the decapeptide
angiotensin I from the parent AGT. Although the parent AGT molecule was
historically thought to have few biologic functions independent of AngI and AngII,
this concept has been recently challenged. (68) AngI is then processed by
angiotensin converting enzyme into the main effector peptide of the renin
angiotensin system, angiotensin II. AngII can be further processed into Ang(1-7)
by angiotensin converting enzyme 2, but AngII is responsible for the majority of
vascular effects. In humans, angiotensin peptides, and specifically AngII, acts on
angiotensinII receptor type 1 (AT1R) and type 2 (AT2R). (69) Mice have two
isoforms of AT1 receptors separated into AT1aR and AT1bR. AT1aR, AT1bR,
and AT2R are seven transmembrane G-protein coupled receptors. While each
isoform has specific functions, previous research indicates that AT1aR drives
pathogenesis in the thoracic aorta. Specifically, deletion of either AT1bR or AT2R
did not alter AngII induced atherosclerosis and aneurysms in either the thoracic
or abdominal aortas. (70, 71) Genetic deletion of AT1aR attenuated AngII
induced aortopathies. (72) Therefore, the main effector peptide of the renin
angiotensin system in the aorta is derived from AGT and the main receptor
isoform responsible for aortopathies is the AT1aR.
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Modulation of the renin angiotensin system, through manipulations of
angiotensin peptides and AT1aR, impacts TAAs. (Table 1.3) In general,
activation of the renin angiotensin system exacerbates TAAs. Exogenous
infusion of AngII induces TAA in C57BL/6J wild type mice and exacerbates TAA
in FBN1C1041G/+ mouse model of Marfan syndrome. (37, 73) Conversely, inhibition
of the renin angiotensin system attenuates TAAs. Losartan, an AT1 receptor
blocker, attenuates TAA in two different mouse models of Marfan syndrome. (64,
74) Endothelial specific deletion of AT1aR attenuated TAA and death by aortic
rupture in the severe FBN1mgR/mgR mouse model of Marfan syndrome. (75) This
effect is highly reproducible. (76-78) Additionally, this phenomenon is
generalizable to other syndromic TAA mouse models, including fibulin-4
deficiency, TGFβ receptor 1 and 2 mutants. (79-81) Therefore, inhibition of RAS
by pharmacologic and genetic means is a promising avenue for ameliorating
TAAs of multiple etiologies.
However, recently published studies indicate that the involvement of the
renin angiotensin system in Marfan syndrome associated TAA may be more
nuanced than previously believed. One key controversy is the involvement of
AT1aR in pathogenesis of Marfan syndrome associated TAA. While the site of
action of AT1aR is still unknown, AT1aR deletion attenuated spontaneous, AngIIinduced TAA. Losartan was shown to be effective in attenuating TAA in a mouse
model of Marfan syndrome. However, losartan is a surmountable prodrug that
may have effects beyond AT1R inhibition. (82) One study claimed that
pharmacologic inhibition of AT1aR using losartan attenuated TAA in a mouse
model of Marfan syndrome through hyperstimulation of AT2R. (83) However,
direct stimulation of AT2R, using a specific agonist compound 21, failed to
attenuate Marfan syndrome associated TAA. (84, 85) This is consistent with
research in spontaneous TAA outlined above and indicates that losartan’s
primary protective effect may not be through AT2R hyperstimulation. Another
study claimed that AT1aR deletion was unable to attenuate TAA in the
FBN1C1041G/+ mouse model of Marfan syndrome. However, losartan was able to
attenuate TAA in AT1aR deficient mice at 6 months of age. (86) This study was
limited by non-standard use of ultrasound and impact was reduced by a failure to
state the sex of mice studied. Small changes in measurement protocols such as
use of different viewing angles in ultrasound can greatly affect reliability of TAA
measurements. Based on studies in the Fbn1GT8/+ model, (56) male and nonparous female have different thoracic aortic dimensions. If treatment groups
included unequal distributions of female and male animals, sexual dimorphism
would hinder comparisons between groups. Directly contradicting this study,
AT1aR deletion in FBN1mgR/mgR mice attenuated both TAA and death by aortic
rupture. (75) Therefore it is unclear whether inhibition of AT1aR alone is sufficient
to attenuate Marfan syndrome associated TAA.
Another controversy is the involvement of angiotensin peptides in
pathogenesis of Marfan syndrome associated TAA. Inhibition of AngII production
by angiotensin converting enzyme inhibitor enalapril attenuates AngII-induced
aneurysms and atherosclerosis. (87) (88) However, AT1aR can be activated in a
cell-stretch activated manner. This can occur by direct stimulation of the AT1
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receptor and can be attenuated by an insurmountable AT1 receptor antagonist.
(89) Activation of the AT1 receptor in this manner is completely independent of
AngII. Cell stretch can also induce autocrine/paracrine release of AngII, thus
activating the AT1 receptor. (90, 91) Evidence for ligand independent activation
of AT1 receptors in Marfan syndrome revolve around the observation that
deletion of AGT does not attenuate dilatated cardiomyopathy in FBN1mgR/mgR
mice. (92) Additionally, ACE inhibitors minimally inhibited TAA in FBN1C1041G/+
mice. (83) Interestingly, clinical data on the efficacy of ACE inhibitors in human
aneurysmal disease is mixed. (93-96) It is unclear whether angiotensin ligands
are critical for the development of Marfan syndrome associated TAA. Ultimately,
it is difficult to separate out ligand-dependent and ligand-independent effects of
AT1aR using ACE inhibitors. ACE, also known as kininase II, can cleave
numerous ligands in addition to AngI. (97) The kinin-kallikrein system plays a role
in inflammation and can counteract the renin-angiotensin system. (98, 99) Thus,
to deplete AngII alone, a novel modality targeting upstream of ACE is needed.
The renin angiotensin system is a complex hormonal system with
numerous players. The paradoxical observations of the benefits in modulating
the renin angiotensin system in Marfan syndrome merit investigation.
Specifically, it is unclear whether AT1aR is involved in development of Marfan
syndrome associated TAA. If AT1aR is involved, it is unclear whether that occurs
in an AngII-dependent or AngII-independent manner.
1.7

Gaps in knowledge, hypotheses tested, and points discussed

Due to lack of understanding in the pathogenesis of Marfan syndrome
associated thoracic aortic aneurysms, there is no effective medical therapy to
reverse aortic dilation. One promising area of investigation is the contribution of
the renin angiotensin system through the action of AngII on AT1aR to
development of Marfan syndrome associated TAAs. However, the gaps in
knowledge include whether and how AT1aR activation is responsible for TAA.
These gaps have remained unfilled due to inadequate standardization of
measurement techniques assaying the ascending aorta. Previous studies have
also been biased due to either exclusive use of male animals or failure to specify
the sex of animals studied. To address these gaps in knowledge this dissertation
tests the overarching hypothesis that deletion of endogenous AngII attenuates
Marfan syndrome associated thoracic aortic aneurysm through inhibition of
ligand-dependent AT1aR activity. We tested this hypothesis by developing
standardized measurements of TAA, investigating the role of the AngII-AT1aR
axis in Marfan syndrome associated TAA, and exploring factors outside the renin
angiotensin system that modulate TAA.
First, we developed and validated standardized methods to assay thoracic
aortic aneurysms. In Chapter 2, we outline the effect of the cardiac cycle on
measurements of the ascending aorta, demonstrating that the expansion of the
aorta during systole is not equivalent between normal and aneurysmal aortas.
Two-dimensional ultrasound is an accurate and precise modality to measure in
vivo aortic diameters. We quantified the degree of expansion, showing that the
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effect of cardiac cycle on aortic measurements can be a significant confounder in
studies with small effect sizes. Additionally, we verify that assessment of elastin
fragmentation by human observers blinded to group allocation is a reliable and
reproducible method not subject to observer bias. Finally, we correlated these
measurements to demonstrate that both luminal dilation and elastin
fragmentation are complementary and consistent measurements of the severity
of thoracic aortic aneurysms. Our subsequent studies benefitted from this
development of standardized protocols for assaying TAAs.
Next, we studied the differential effects of inhibiting ligand-dependent and
ligand-independent AT1aR activity of TAA in FBN1C1041G/+ mice. Our hypothesis
was that inhibition of the AngII-AT1aR axis is sufficient to attenuate TAA in
FBN1C1041G/+ mice. These studies are outlined in Chapter 3. Interestingly, we
noticed striking sexual dimorphism in FBN1C1041G/+ mice, causing us to pursue
studies in male mice to maximize study power. Next, we generated FBN1C1041G/+
mice with AT1aR deficiency alongside AT1aR intact mice to investigate the
contribution of AT1aR. Using our validated methods of assaying TAA, we
measured aortic diameters up to 12 months and elastin fragmentation in the
ascending aorta at study termination. We found that ablation of both liganddependent and ligand-independent attenuated TAA in male FBN1C1041G/+ mice.
To distinguish between ligand-dependent and ligand-independent effects of
AT1aR, we used a novel antisense oligonucleotide targeted against
angiotensinogen to deplete plasma AGT. Depletion of AGT is male FBN1C1041G/+
mice was sufficient to attenuate TAA, indicating that angiotensin ligands play a
critical role in TAA pathogenesis.
Finally, we explored and discussed modulating factors of TAA. Although
the renin angiotensin system is a major mediator of vascular homeostasis, other
systemic and cell-specific factors may increase or decrease severity of Marfan
syndrome associated TAA. One hypothesis is that estrogens were protective and
androgens exacerbated TAA. Sex hormone removal impacted sexual
dimorphism in TAA mouse models. Gonadectomy reduces endogenous sex
hormones and causes atrophy of sex responsive organs. Ovariectomy of female
mice exacerbated AngII-induced TAA. Orchiectomy of male mice attenuated
AngII-induced TAA. However, gonadectomy was unable to alter existing TAA in
juvenile FBN1mgR/mgR mice due to the model’s aggressive TAA development.
Another hypothesis is that AngII acts on AT1aR within the vascular wall, and
specifically on adventitial fibroblasts to induce TAA. Previous research indicates
that deletion of AT1aR on smooth muscle cells has no effect on TAA. (17, 75,
100) Additionally, endothelial specific deletion of AT1aR had marginal attenuation
of Marfan syndrome associated TAA. Our evidence indicates that fibroblast
specific deletion of AT1aR (driven by s100a4-cre) attenuates AngII induced
aortopathies but not Marfan syndrome associated TAA. Thus, the cell type
responsible for TAA in Marfan syndrome is still elusive and may differ from TAA
of other etiologies. Altogether, these modulating factors, both the impact of sex
hormones and the contribution of cell specific AT1aRs, represent interesting
associations that need further exploration.
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The studies outlined in this dissertation reveal novel insights into factors
that modulate TAA. In discussing the conclusions of these findings, we will
critically inspect these studies for limitations as well as propose future directions
that can be taken given these revelations. Possible future studies may include
use of AGT ASOs in human trials, determining the source of increased AngII in
Marfan syndrome aortas, and determining the cell type responsible for AT1aR
stimulation in Marfan syndrome. These findings are significant not only for
increasing our understanding of the pathogenesis of Marfan syndrome
associated thoracic aortic aneurysms but also for outlining novel treatment
modalities that we hope to ultimately blunt the progression of this disease.
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Table 1.1 Conserved domains in fibrillin-1
Conserved
Function
Domain
Fibrillin unique
Binding to fibrillin family C-terminus
N-terminus
domain
Binding site for heparin sulfate proteoglycans
Fibronectin dependent microfibrillar assembly
EGF/cbEGF
Calcium dependent structural rigidity under
domains
tension
TGFβ bindingIntegrins α5β1, αvβ3, and αvβ6 binding site
like domain
Weak calcium binding, structural rigidity
Hybrid
Calcium binding, structural rigidity
domains
Proline/glycine
Unique identifiers between fibrillin family
rich domains
members
tropoelastin binding
C-terminal
Furin cleaved endocrine regulator of glucose
and Aprosin
homeostasis
Latent TGFβ binding protein interaction site
ADAMTS interaction site
BMP family binding site
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Refs
(101)
(102)
(103)
(102, 104)
(102, 105)

(102)
(103)
(102)

Table 1.2 Mutant microfibril mouse models and phenotypes
Protein
Mouse Models
Mutation
Aortic Phenotype Reference
Elastin
Tropoelastin
ELN -/Null
Aortic occlusion
(106)
and tortuosity
ELN +/Null
Aortic occlusion
(107)
and tortuosity
SM22-ELN-/Cell specific
Aortic occlusion
(18)
deletion
and tortuosity
Tie2-ELN-/Cell specific
Disrupted IEL
(18)
deletion
Cdh5-ELN-/Cell specific
Disrupted IEL
(18)
deletion
Fibrillins
Fibrillin-1
FBN1
Hypomorphic
Severe TAA
(12)
mgR/mgR
FBN1
Missense
TAA
(11)
C1041G/+
FBN1 GT8/+
Truncation
TAA
(52)
FBN1 H1Δ
Exon 7
Unknown (52)
deletion
perinatal lethal
FBN1mgΔ
Exon 19-24
Unknown (51)
deletion
perinatal lethal
FBN1 -/Null
Perinatal systemic
(108)
vascular
compromise
Fibrillin-2
FBN2 -/Null
None
(108)
Fibulins
Fibulin-1

FBLN1 -/-

Null

Fibulin-2
Fibulin-3
Fibulin-4

FBLN2 -/FBLN3 -/FBLN4 -/-

Null
Null
Null

Fibulin-5
EMILIN
EMILIN-1

FBLN5 -/-

Null

EMILIN-1 -/-

Null

EMILIN -2

EMILIN-2 -/-

Null

EMILIN -3

EMILIN-3 -/-

Null
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Aortic Rupture perinatal lethal
None
None
TAA, perinatal
lethal
Tortuous Aorta
Elastin
fragmentation
Not characterized;
not expressed in
aorta
Not characterized;
not expressed in
aorta

(109)
(110)
(111)
(112, 113)
(114)
(115)
(116)
(117)

Table 1.3 Mouse Models Where AT1aR Inhibition Attenuates TAA
TAA Model
AT1 Inhibition Modality
Reference
FBN1C1041G/+

Losartan

(64)

AngII-infused

AT1a receptor deletion

(118)

Transverse Aortic
Constriction
DOCA-Salt

Losartan

(119)

Losartan

(39)

Tgfbr2G357W/+

Losartan

(81)

Fibulin4R/R

Losartan

(120)

FBN1mgR/mgR

Losartan

(74)

FBN1mgR/mgR

AT1a receptor deletion

(75)
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CHAPTER 2. MAJOR METHODS OF MEASURING TAA
This chapter is based on a previously published manuscript:
Chen JZ, Sawada H, Moorleghen JJ, Weiland M, Daugherty A, Sheppard MB.
Aortic strain correlates with elastin fragmentation in Fibrillin-1 hypomorphic mice.
Circ Rep. 2019;1(5):199-205. doi: 10.1253/circrep.CR-18-0012. PubMed PMID:
31123721; PMCID: PMC6528667.
2.1

Synopsis

Background: High frequency ultrasound has facilitated in vivo measurements of
murine ascending aortas, allowing aortic strains to be gleaned from twodimensional images. Thoracic aortic aneurysms associated with mutations in
fibrillin-1 (FBN1) display elastin fragmentation, which may impact aortic strain. In
this study, we determined the relationship between elastin fragmentation and
aortic circumferential strain in wild type and fibrillin-1 hypomorphic (FBN1mgR/mgR)
mice.
Methods and Results: Luminal diameters of the ascending aorta from wild type
and FBN1 hypomorphic (FBN1mgR/mgR) mice were measured in systole and
diastole. Expansion of the ascending aorta during systole in male and female
wild type mice was 0.21±0.02 mm (16.3%) and 0.21±0.01 mm (17.0%)
respectively, while expansion in male and female FBN1mgR/mgR mice was
0.11±0.04 mm (4.9%) and 0.07±0.02 mm (4.5%) respectively. Reduced
circumferential strain was observed in FBN1mgR/mgR mice compared to wild type
littermates. Elastin fragmentation was inversely correlated to circumferential
strain (R^2 = 0.628 p = 0.004) and significantly correlated with aortic diameter.
(R^2 = 0.397, p = 0.038 in systole and R^2 = 0.515, p =0.013 in diastole)
Conclusions: FBN1mgR/mgR mice had increased aortic diameters, reduced
circumferential strain, and increased elastin fragmentation. Elastin fragmentation
in FBN1mgR/mgR and their wild type littermates was correlated with reduced
circumferential strain.
2.2

Introduction

Thoracic aortic aneurysms (TAAs) are abnormal dilations of the aorta
associated with increased risk of life-threatening aortic dissection and
rupture.(36) While the majority of TAAs have not yet been associated with a
specific mutation, TAAs often occur in the context of inherited genetic disorders
such as Marfan syndrome. TAA tissues from patients with Marfan syndrome
display decreased aortic elasticity.(121) Measurement of aortic diameter is a
critical prognostic indicator as larger diameters are associated with higher risk of
rupture.(36)
Mouse models of spontaneous TAAs can be generated by systemic
administration of chemicals such as angiotensin II (AngII) or β23

aminopropionitrile.(37, 38) Mouse models of heritable TAAs can be generated by
manipulation of genes responsible for extracellular matrix integrity or smooth
muscle cell function such as fibrillin-1, fibulin-4, and ACTA-2.(11, 12, 47, 113,
122) In this study we used the fibrillin-1 hypomorphic (FBN1mgR/mgR) mouse
model, which aggressively develop TAA early in life. Previous studies in these
mice have revealed decreased elastin expression and increased elastin
fragmentation in aneurysmal tissue. (12, 77, 123-125) This elastin fragmentation
may influence aortic circumferential strain. We hypothesized that vascular strain
in the ascending aorta, measured by two-dimensional high frequency ultrasound,
correlated with elastin fragmentation. To test this hypothesis, we compared
circumferential aortic strains in the FBN1mgR/mgR mice, which naturally develop
elastin fragmentation, versus sex-matched wild type littermates.
Aortic diameter measurements are the primary endpoint to quantify TAA
severity in disease models. Previously, ascending aortic measurements in mice
were limited to terminal endpoints.(126, 127) This included measurements of
aortic elasticity and sheer strain performed on ex vivo tissues. (77) Development
of high frequency ultrasound, in the range of 40-50 MHz, has enabled resolution
that distinguishes small changes of aortic dimension over sequential
measurements.(17) This resolution allows measurements of circumferential
strain from two-dimensional images captured in vivo and enables investigation of
the impact of elastin fragmentation on aortic strain.
This study used two-dimensional, trans-thoracic ascending aortic
ultrasound measurements of the ascending aorta in wild type mice and their
FBN1mgR/mgR littermates to measure circumferential strain in vivo. When
standardized, two-dimensional, trans-thoracic ascending aortic ultrasound
measurements correlate closely with traditional ex vivo measurements and have
low interobserver variability. (34) Finally, we determined the correlation of these
findings to elastin fragmentation.
2.3

Methods

Mice

Male and female wild type (WT) C57BL/6J and FBN1mgR/mgR littermates
were generated at The Jackson Laboratory (Bar Harbor, ME) from stock #
005704. Heterozygous FBN1mgR/+ males were bred with FBN1mgR/+ females to
generate mice of desired genotypes. Mice were fed standard laboratory diet and
water ad libitum and maintained on a 14:10 hour light:dark cycle. Mice were
transferred to a barrier facility at the University of Kentucky. All protocols were
approved by the University of Kentucky IACUC.
Non-invasive blood pressure measurements
Systolic blood pressure was measured by tail cuff using a Kent Scientific
Coda 8 as described previously.(128) All measurements were performed at the
beginning of the light cycle. Briefly, mice were restrained and placed on a
warming platform. Twenty cycles of blood pressure measurements were obtained
for each mouse. Measurements <50 mmHg and >220 mmHg were excluded.
24

Pulse rates <400 bpm were excluded from calculation. Blood pressures were
measured on 3 consecutive days at the same time of day. Measurements
represented means over 3 days.
Ultrasound measurements
Ultrasound images were acquired in wild type and FBN1mgR/mgR mice at 11
weeks of age. Mice were anesthetized using isoflurane; dose was titrated
between 2-3% wt/vol isoflurane with 2 L/min O2 to maintain a heart rate of 400 500 beats per minute as monitored by concurrent three lead electrocardiogram
(ECG). Ultrasound cine-loops were captured using a Vevo 2100 system with a
MicroScan MS550 40 MHz transducer (VisualSonics, Toronto, ON). Frame rate
was at least 300 frames per second and 300 frames were stored per cine-loop.
Aortic images were acquired from a modified right parasternal long axis view (1 –
2 ribs caudal to the right parasternal long axis view, Figure 2.1). The probe was
angled 45 degrees relative to the chest to avoid sternum artefacts. Images were
standardized to include visualization of two anatomical landmarks: the
innominate artery and aortic valve (Figure 2.2A). The ascending aorta was
defined as the region between the sinotubular junction and the innominate artery.
The largest ascending aortic diameter was measured in both systole and diastole
of 3 separate cardiac cycles for each mouse. To facilitate measurements, a
center line was drawn on the acquired image at the midpoint between the aortic
walls. Aortic diameters (AoD) were measured at the largest diameter
perpendicular to the center line of the aorta (Figure 2.2B). AoD in systole
(AoD;s) was measured at physiologic systole: when aorta was maximally dilated.
AoD in diastole (AoD;d) was measured at the end of diastole: defined as during
the R wave (Figure 2.2C). Aortic images were analyzed by two independent
observers that were blinded to the experimental groups. Circumferential strain
was calculated as previously described using Equation 1.(129)
𝐴𝐴𝐴𝐴𝐴𝐴;𝑠𝑠 2

(1)

0.5 ��𝐴𝐴𝐴𝐴𝐴𝐴;𝑑𝑑� − 1� ∗ 100%

Ex vivo aortic measurements
Mice were terminated by overdose of ketamine:xylazine at 11 weeks of
age followed by exsanguination via cardiac puncture and saline perfusion. Aortas
were dissected away from surrounding tissue and Optimal Cutting Temperature
Compound (Sakura Finetek, Torrance, CA) was slowly introduced via the left
ventricle to maintain aortic patency. A black plastic sheet was inserted behind the
aorta and heart to increase contrast and facilitate visualization of aortic borders.
Aortas were immediately imaged using a Nikon SMZ800 stereoscope and
measurements were recorded using NIS-Elements AR 4.51 software (Nikon
Instruments Inc., Melville, NY). Fluid OCT maintained aortic patency to facilitate
ex vivo and histologic analyses. Ascending aortic diameters were measured at
the largest width perpendicular to the vessel.
Quantification of elastin fragmentation
Three proximal thoracic aortas per group were selected randomly and at
least nine tissue sections per aorta were generated using a cryostat. Tissue
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sections (10 µm) were generated from the aortic root to the aortic arch at 100 µm
intervals. Three sections corresponding to the region of largest dilation between
the sinotubular junction and the arch were analyzed. Briefly, elastin was
visualized by auto-fluorescence by an excitation spectrum of 460 – 500 nm.
Multiple high magnification images were acquired of each section that were
subsequently aggregated to a single image of the entire section using
ImageJ.(130) Fragmentation was defined as the presence of discernable breaks
of continuous elastin fiber. The number of elastin breaks was counted by two
independent investigators who were blinded to the sample identification.
Individual data were represented as the mean number of elastin breaks per aortic
section calculated by two independent investigators.
Statistics
Data are reported as mean ± standard error. Statistical analyses were
performed using SigmaPlot (Systat Software Inc; San Jose, CA). For two-group
comparisons, all data passed normality and equal variance tests. Paired
Student’s t-tests were used to compare systole and diastole from the same
mouse and unpaired Student’s t-tests were used between groups. P < 0.05 was
considered statistically significant. Regression was calculated via Pearson’s
Coefficient of Correlation. Bland-Altman analysis was performed by plotting the
mean of aortic diameter measured ex vivo and by ultrasound versus the
difference of aortic diameter measured ex vivo and by ultrasound with negative
values indicated that ex vivo measurements are smaller than ultrasound
measurements. (Equation 2) Bias and limits of agreement calculated for BlandAltman analyses compared measurements of the same biological variable that
had been obtained using two different measurement methods.
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 = 𝑒𝑒𝑒𝑒 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 − 𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 (2)
2.4

Results

Wild type and FBN1mgR/mgR mice exhibited similar body weight and systolic blood
pressure at 11 weeks of age.
Systolic and diastolic blood pressures were measured by tail-cuff at 11
weeks of age in mice for 3 consecutive days before termination at similar times of
the day. Blood pressure was not significantly different in wild type and
FBN1mgR/mgR sex-matched littermates. In addition, body weights were not
different between wild type and FBN1mgR/mgR sex-matched littermates (Table 2.1).
During ultrasonography, anesthesia was titrated to maintain a heart rate of 400500 beats per minute. Therefore, heart rate was not significantly different
between groups during ultrasonography (Heart rate wild type = 453 ± 27 bpm;
FBN1mgR/mgR = 439 ± 26 bpm; p = 0.86). Heart rates during ultrasound were
lower than normal due to anesthesia effect. Heart rates were also not different
between groups during non-invasive blood pressure measurements (Table 2.1).
Two-dimensional ultrasound measurements of the ascending aorta in
FBN1mgR/mgR mice.
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Ultrasound measurements of ascending aortas of 11 week old male and
female wild type mice and their FBN1mgR/mgR littermates in systole and diastole
were measured via a standardized protocol described above (Figure 2.3, A – D).
Ascending aortic diameters measured in systole were significantly greater than
those measured in diastole (Figure 2.3, E and F) in both male and female mice.
(Table 2.1) The difference between systole and diastole in wild type mice was
larger than in FBN1mgR/mgR sex-matched littermates.
Ascending aortas from FBN1mgR/mgR mice demonstrated less circumferential
strain during systole.
Fibrillin-1 hypomorphic mice exhibited significantly less circumferential
expansion during systole compared to their wild type littermates. GreenLagrange strain was calculated using equation 1 from aortic diameters obtained
from B-mode images of systole and diastole from each individual mouse.
Increased circumferential strain was observed in WT ascending aortas compared
to aortas from FBN1mgR/mgR mice (Figure 2.4, A and B). This effect was seen in
both male and female mice. In male mice: mean percent strain wild type = 18.2 ±
1.8%; FBN1mgR/mgR = 5.9 ± 2.4%; p = 0.001. In female mice: mean percent strain
wild type = 17.4 ± 1.9%; FBN1mgR/mgR = 5.4 ± 1.8%; p = 0.001.
Elastin fragmentation correlates inversely with circumferential strain and
positively with aortic diameter.
As expected, aortic sections from FBN1mgR/mgR mice displayed significantly
greater elastin fragmentation compared to their wild type counterparts. (Figure
2.5, A – C). Elastin fragmentation was also significantly inversely correlated to in
vivo circumferential strain (R2 = 0.628 p = 0.004) and positively correlated to both
systolic and diastolic aortic diameters (R2 = 0.397, p = 0.038 in systole and R2 =
0.515, p =0.013 in diastole) (Figure 2.5, D – F). By fitting a multiple linear
regression model, we also determined that the FBN1 genotype contributed
significantly to differences in elastin fragmentation (p = 0.001) and that elastin
fragmentation did not correlate with sex (p = 0.414).
2.5

Discussion

Previously, our group reported aortic diameters in aneurysm studies without
specifying the cardiac phase during which these in vivo measurements were
taken.(17, 70, 131, 132) In this study, we demonstrated that in vivo two
dimensional ultrasound measurements are accurate and correlate with in situ
measurements of exposed aortas. (Figure 2.6) Furthermore, we quantified the
difference between measurements taken in systole and diastole in the thoracic
aorta. (Figure 2.3) This suggested that two-dimensional trans-thoracic
ultrasound can be used to calculate circumferential aortic strain, despite the fact
that the thoracic aorta experiences increased longitudinal displacement due to its
proximity to the beating heart.(129, 133) Using a mouse model of elastin
fragmentation, we further investigated whether differences in aortic strain
between FBN1mgR/mgR mice and their wild type littermates correlated with elastin
fragmentation.
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Previously, circumferential strain has been characterized in the AngIIinduced mouse model of aortic aneurysms.(134) However, these analyses have
not been performed for mouse models of heritable thoracic aortic aneurysms,
such as FBN1mgR/mgR mice. FBN1mgR/mgR mice were used in this study because of
the rapid development of pronounced thoracic aneurysms. (12, 51) Mouse
models with mutations in FBN1 exhibit decreased aortic elastin expression,
elastin fragmentation, and TAAs.(77) Aortas from wild type mice experienced
greater circumferential strain during systole compared to aortas from
FBN1mgR/mgR mice. In this study, systolic blood pressure was acquired using a
standardized protocol on a system that measures the variance in tail volume in
conjunction with a pressure cuff.(128) We have demonstrated previously that
there is good correlation between blood pressure measurements obtained by this
process compared to those obtained by telemetry.(135) Although absolute blood
pressure measurements can differ between instruments, there were no
differences detected in systolic blood pressure between wild type and
FBN1mgR/mgR mice. There was also no statistical significant difference in heart rate
measured while conscious or under anesthesia. The correlation between blood
pressure and circumferential strain was not significant. However, blood pressures
were not measured during ultrasound. We cannot assume that blood pressure in
the awake state is equal to blood pressures during ultrasound in the anesthetized
state. While this suggests that the increase in aortic stiffness is a function of
intrinsic aortic tissue mechanics, this point merits further study. Indeed, this
increase in aortic stiffness has been measured in other mouse models of
spontaneous thoracic and abdominal aortic aneurysm and dissection. In fact,
circumferential aortic strain in the AngII-induced mouse model of abdominal
aortic aneurysms is approximately 15% in control mice and 5% in AngII infused
mice.(134) These strains are consistent when measured by speckle tracking
technology.(136) Interestingly, AngII-induced thoracic aortic aneurysms also had
reduced circumferential strain. Circumferential strains in this model decrease
from 20% before infusion to 10% after AngII infusion.(137) Data from AngIIinduced aortic aneurysms are in agreement with our results in a heritable model
of thoracic aortic aneurysm.
Strains have been measured ex vivo in the FBN1mgR/mgR mouse model.
Previously, Lee et al.(77) demonstrated that compressive forces, measured by
atomic force microscopy acting on aortas from FBN1mgR/mgR mice, produced
greater deformation under stress.(77) This was attributed to the loss of elasticity
in FBN1mgR/mgR aortas as evidenced by reduced area fraction of elastic fibers. We
quantified elastin fragmentation as a proxy of aortic elastic behavior. While
elastin fragmentation was correlated with reduced circumferential strain in
response to circumferential tensile forces in vivo, this analysis is limited by the
assumption that loss of continuous elastin layers leads to loss of elasticity.
Paradoxically, loss of elasticity can explain both the loss of resistance to
compressive forces outlined by Lee et al.(77) and the increased resistance to
circumferential tensile forces shown in this study via the Poisson effect.
Together, these observations imply that increased elastin fragmentation in
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FBN1mgR/mgR aortic tissue may be responsible for reduced aortic strain observed
during systole in FBN1mgR/mgR mouse.
The primary purpose of this study was to determine the relationship
between circumferential aortic strain measured in vivo and elastin fragmentation.
We additionally quantified aortic diameter increases during systole compared to
diastole in both wild type and FBN1mgR/mgR mice. The significant size differences
indicate that cardiac cycle influences interpretation of murine studies that report
thoracic aortic diameters. Based on our data, the excursion of the aorta in systole
can be as great as 0.2 mm in wild type aortas and 0.1 mm in aneurysmal aortas.
This difference is larger than error attributable to interobserver variability in our
dataset, where bias between observers was 0.08 ± 0.08 mm in systole and -0.07
± 0.06 mm in diastole (Figure 2.7). Thus, specifying whether ascending aortic
diameter were measured in either systole or diastole is especially important in
studies in order to detect small differences, ensure accuracy, and increase study
power. Accounting for this phenomenon is important when ascending aortic
diameter measured across different studies. This discrepancy occurs because
studies have reported aortic diameters in systole, diastole, both, or omit reporting
cardiac cycle.(17, 137-140) In lieu of these data, a correction factor of
approximately 17% in C57BL/6J wild type aortas and 5% in FBN1 mgR/mgR
aneurysmal aortas may be taken to approximate measurements taken in systole
compared to diastole.
This study used mice that spontaneously develop elastin fragmentation to
demonstrate that reduced circumferential strain is correlated with increased
elastin fragmentation and that two- dimensional ultrasound data can be used to
measure circumferential strain in vivo.
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Table 2.1 Characteristics of wild type and FBN1mgR/mgR mice
Sex

Systolic
Blood
Pressure
(mmHg)

Aortic
Pulse
Diameter;
Rate
Systole
(bpm)
(mm)

Aortic
AoD;s
Diameter;
–
Diastole AoD;d
(mm)
(mm)

Genotype

N

Age at
Ultrasound (d)

Body
Weight
(g)

WT

8

74.8 ± 1.0

25.7 ±
0.5

147 ± 7

506 ±
1.50 ± 0.05
23

1.29 ±
0.05***

0.21 ±
0.02

8

74.8 ± 1.0

26.2 ±
0.8

139 ± 18

524 ±
2.35 ± 0.13
31

2.24 ±
0.15**

0.11 ±
0.04*

5

74.7 ± 1.3

20.5 ±
0.7

137 ± 9

547 ±
1.42 ± 0.03
58

1.23 ±
0.04***

0.21 ±
0.01

7

75.2 ± 1.2

20.8 ±
0.8

125 ± 13

443 ±
1.64 ± 0.07
23

1.57 ±
0.08**

0.07 ±
0.02*

Male
FBN1

mgR/mgR
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WT
Female
FBN1

mgR/mgR

Male and female FBN1 wild type (WT) and FBN1mgR/mgR mice were aged to 11 weeks. Body weight was measured
before performing ultrasonography. SBP and pulse rate were measured for 3 consecutive days using a tail cuff-based
technique. No measurements were significantly different between wild type and FBN1mgR/mgR within sex. Aortic diameters
in systole and diastole were measured as described above. Male mice: wild type p < 0.001; FBN1mgR/mgR p = 0.004.
Female mice: wild type p < 0.001; FBN1mgR/mgR p = 0.009. ***p<0.001, ** p<0.01 AoD;s vs AoD;d. AoD difference was
calculated by AoD;s – AoD;d. In male mice: AoD difference between wild type and FBN1mgR/mgR, p = 0.03. Female mice, p
= 0.01. * p<0.05 WT vs FBN1mgR/mgR . Measures are represented as mean ± SEM. p > 0.05 between groups via Student’s
t-test.

Figure 2.1 Probe positions used to measure aortic diameter.
Aortas from a 12 week old wild type (WT) mouse was imaged in A, C) right
parasternal long axis and B, D) left parasternal long axis views. Modified long
axis views were taken from a location that was one to two ribs above the long

axis view to optimize visualization of the ascending aorta. Red arrows point to the
ascending aorta.
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Figure 2.2 Modified right parasternal long axis view and measurement
protocol of the ascending aorta.
A) B-mode images were standardized to include visualization of two distinct
anatomical landmarks in the same field: the aortic valves and the innominate
artery. B) Center line was defined as the midpoint between aortic walls (blue
line). Measurements were taken inner-edge to inner-edge at the largest diameter
(red line) perpendicular to the center line between the aortic root and innominate
artery. Yellow lines depicting the aortic vessel wall were included for clarity in this
diagram, but were not used for measurement purposes. Green bar = 1 mm. C)
Concurrent ECG monitoring allowed standardization of end-diastole (dashed red
line one frame within the QRS complex) to facilitate imaging at a specific interval
of the cardiac phase. Images at systole were taken at physiologic systole.
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Figure 2.3 Effect of cardiac cycle on ascending aortic diameters.
A – D) Representative B-mode images of ascending aortas from 11 week old
wild type (WT) and FBN1mgR/mgR mice. Quantification of aortic diameters in
systole and diastole of E) male and F) female littermates. There were significant
differences in aortic diameters between systole and diastole within both sex and
genotype. Red line = region measured, green bar = 1 mm. Male: n = 8 WT and 8
FBN1mgR/mgR; Female: n = 5 WT and 7 FBN1mgR/mgR; ***p < 0.001, *p < 0.05
between groups by paired Student’s t-test.
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Figure 2.4 Circumferential Green-Lagrange strain of the aorta during
cardiac cycle in wild type and FBN1mgR/mgR mice.
Percent expansion was calculated by comparing aortic measurements between
systole and diastole within a cardiac cycle. A) Male and B) female wild type (WT)
mice exhibited greater percent expansion during the cardiac cycle compared to
their FBN1mgR/mgR littermates. Male: n = 8 WT and 8 FBN1mgR/mgR; Female: n = 5
WT and 7 FBN1mgR/mgR; **p < 0.01 between groups by Student’s t-test.
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Figure 2.5 Elastin fragmentation of WT and FBN1mgR/mgR correlated with
ascending aortic diameter.
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A, B) Representative images of elastin fragmentation from WT and FBN1mgR/mgR
mice acquired by elastin autofluorescence at the largest ascending aortic
diameter. Green line = 100 µm. C) Elastin fragmentation quantified D) Correlation
analysis of elastin fragmentation versus circumferential strain revealed an
inverse relationship. (R2 = 0.628, p = 0.004). E, F) Correlation plots of elastin
breaks compared to aortic diameter in systole and diastole. n = 3 male WT, male
mgR, and female WT. n = 2 female mgR. R2 = 0.397, p = 0.038 in systole and R2
= 0.515, p =0.013 in diastole. Male and female WT = blue and green circles.
Male and female FBN1mgR/mgR = yellow and red triangles respectively.
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Figure 2.6 Ultrasonographic measurements of aortic diameter in diastole
closely reflected ex vivo aortic diameter measurements.
Representative images of in situ aortas from A) WT and B) FBN1mgR/mgR mice in
which measurements were recorded at the largest ascending aortic diameter.
Red line = region measured, green line = 1 mm. C, D) Bland-Altman analyses
demonstrated that in situ diameters correlated more closely to ultrasonographic
measurements in diastole than systole. (Bias in systole = -0.21 mm; in diastole =
-0.05 mm). Measurements were less reliable at larger aortic diameters as shown
by the divergence from bias in the Bland-Altman plot in ascending aortic
diameters greater than 1.8 mm. Center blue line represents bias and outer blue
lines represents the 95% limits of agreement. Male and female WT = blue and
green circles. Male and female FBN1mgR/mgR = yellow and red triangles
respectively.
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Figure 2.7 Bland-Altman analyses comparing measurements obtained by
two independent observers that were blinded to the experimental design.
A, B) Measurements between observers in both systole and diastole were highly
correlated. Systole R2 = 0.976; Diastole R2 = 0.988; p <0.001 C, D) Bland-Altman
analyses of ascending aortic B-mode image measurements acquired by two
independent, observers, who were blinded to the image identification,
demonstrated negligible bias in systole and diastole. Bias in systole = 0.08 ± 0.08
mm ; diastole = -0.07 ± 0.06 mm. Limit of agreement 95% CI [-0.70, 0.26] mm in
systole and [-0.19, 0.04] mm in diastole) n = Aggregate measurements from 28
mice. The center blue line represents bias and outer blue lines represents the
95% limits of agreement.
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CHAPTER 3. INHIBITION OF ANGIOTENSIN II-DEPENDENT AT1A RECEPTOR
STIMULATION ATTENUATES THORACIC AORTIC DILATATION IN FIBRILLIN-1C1041G/+
MICE
This chapter contains information adapted from a provisional patent application
titled “TREATMENT USING ANGIOTENSINOGEN ANTISENSE
OLIGONUCLEOTIDE” to Alan Daugherty, Mary Sheppard, Hong Lu, and Jeff
Chen for describing use of a pharmacologic agent in Marfan syndrome
associated thoracic aortic aneurysms.
This chapter is also based on a publication in process titled “Inhibition of
Angiotensin II Dependent AT1a Receptor Stimulation Attenuates Thoracic Aortic
Pathology in Fibrillin-1C1041G/+ Mice” detailing the central finding that inhibition of
the AngII- AT1a receptor axis attenuates Marfan syndrome associated thoracic
aortic aneurysms.
3.1

Synopsis

Objective:
A cardinal feature of Marfan syndrome is thoracic aortic aneurysm (TAA).
The contribution of ligand-dependent stimulation of angiotensin II receptor type
1a (AT1aR) to TAA progression remains controversial because the beneficial
effects of angiotensin receptor blockers have been ascribed to off-target effects.
This study used genetic and pharmacologic modes of attenuating angiotensin
receptor and ligand, respectively, to determine their roles on TAA in mice with
fibrillin-1 haploinsufficiency (Fbn1C1041G/+).
Approach and Results:
TAA in Fbn1C1041G/+ mice were determined in both sexes and found to be
strikingly sexually dimorphic. Males displayed progressive dilation over 12
months while ascending aortic dilation in Fbn1C1041G/+ females did not differ
significantly from wild type mice. To determine the role of AT1aR, Fbn1C1041G/+
mice that were either +/+ or -/- for AT1aR were generated. AT1aR deletion
reduced progressive expansion of ascending aorta and aortic root diameter from
1 to 12 months of age in males. Medial thickening and elastin fragmentation were
attenuated. An antisense oligonucleotide against angiotensinogen (AGT-ASO)
was administered to male Fbn1C1041G/+ mice to determine the effects of
angiotensin II depletion. AGT-ASO administration, at doses that markedly
reduced plasma AGT concentrations, attenuated progressive dilation of the
ascending aorta and aortic root. AGT-ASO also reduced medial thickening and
elastin fragmentation.
Conclusions:
Genetic approaches to delete AT1aR and deplete AngII production
exerted similar effects in attenuating pathology in the proximal thoracic aorta of
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male Fbn1C1041G/+ mice. These data are consistent with ligand (AngII) dependent
stimulation of AT1aR being responsible for aortic disease progression.
3.2

Introduction

Marfan syndrome is an autosomal dominant genetic disorder associated
with thoracic aortic aneurysm (TAA) that enhance the risk for aortic rupture due
to loss of aortic integrity.(141) The disease is caused by mutations in fibrillin-1; a
protein incorporated into the microfibrils that decorate elastic fibers.(142) To gain
insight into the mechanisms of the disease, mice have been developed with a
heterozygous expression of the C1041G mutation of the mouse fibrillin-1 protein,
which is analogous to the C1039Y mutation in humans.(11) These mice have a
haploinsufficiency of fibrillin-1 and mimic some pathologies present in patients
with Marfan syndrome including progressive expansion of the proximal thoracic
aorta.
The renin angiotensin system has been invoked as a mediator of TAA in
patients with Marfan syndrome.(143) Experimental evidence for the role of the
renin angiotensin system has been based predominantly on the observation that
losartan inhibits aortic pathology in mice. This was demonstrated initially in
Fbn1C1041G/+ mice administered losartan starting at the prenatal phase of life.(64)
Additionally, it has been consistently demonstrated that losartan reduces aortic
expansion in many other mouse models of TAA. (74, 81, 83, 86, 119, 120)
However, losartan’s many well-characterized effects independent of AT1
receptor antagonism potentially hinder its use as a pharmacologic tool to
specifically study AT1 receptors.(144) Indeed, the benefit of losartan in inhibiting
aortic root dilation in Fbn1C1041G/+ mice has been attributed to effects such as
TGF-β antagonism or nitric oxide synthase stimulation.(64, 86) To overcome the
limitations of pharmacological approaches, there is a critical need to determine
the role of AT1aR using genetic deletion to specifically ascribe a function of AT1
receptors in general and AT1aR specifically.
Additionally, the mode by which AT1 receptors become activated in
Marfan syndrome is uncertain. While activation of AT1 receptors is commonly
due to engagement of the ligand, angiotensin II (AngII), the pathway can also be
activated by conformational changes of the protein during cell stretch of
myocytes and vascular smooth muscle cells.(145-147) This stretch activation of
AT1 receptor is inhibited by pharmacological antagonists of the receptor. Based
on studies in angiotensinogen deficient mice, dilated cardiomyopathy in the
fibrillin-1 hypomorphic model of Marfan syndrome has been attributed to this
AngII-independent activation of AT1aR.(92) The relative role of receptor
activation of ligand versus stretch has not been evaluated in vascular disease.
The aim of the present study was to define the contribution of liganddependent activation of AT1aR to the progressive expansion of the proximal
thoracic aorta in Fbn1C1041G/+ mice. Aortic diameters were measured for a 1 year
interval using a standardized ultrasound protocol.(34, 35) In accord with current
guidelines, the study was performed in both sexes of these mice. These studies
demonstrated a strong sexual dimorphism with greater expansion in Fbn1C1041G/+
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males and minimal progressive expansion in Fbn1C1041G/+ females. Surprisingly,
this disparity has not been reported previously. The role of AT1aR was
determined subsequently using male mice with global AT1aR deletion. The role
of the ligand was determined using an angiotensinogen antisense oligonucleotide
(AGT-ASO) that depleted the unique precursor of AngII. This study demonstrated
the importance of ligand-dependent activation of AT1aR to progression of aortic
pathology.
3.3

Methods

Mice

Studies were performed in accordance with recommendations for design
and reporting of animal aortopathy studies.(32, 33) Studies were performed using
littermate controls. Mice and genealogy were tracked with Mosaic Vivarium
Laboratory Animal Management Software (Virtual Chemistry). Male and female
AT1aR deficient (AT1aR-/-) (stock #002682) and Fbn1C1041G/+ (stock #012885)
mice were obtained from The Jackson Laboratory. Male AT1aR heterozygous
(AT1aR+/-) x Fbn1C1041G/+ were bred with female AT1aR+/- x fibrillin-1 wild type
(Fbn1+/+) mice to generate four experimental groups per sex: male and female
AT1aR wild type (AT1aR+/+) x Fbn1+/+, AT1aR-/- x Fbn1+/+, AT1aR+/+ x
Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+ mice. Littermates were separated by
sex and genotypes and were randomized when housing mice after weaning. For
AGT ASO experiments, 2-month-old male Fbn1C1041G/+ mice were procured from
The Jackson Laboratory and randomized into experimental groups using a
random number generator. Mice were checked daily for health, and necropsy
was performed to adjudicate cause of death. Mice were housed up to 5 per cage
and maintained on a 14:10 hour light:dark cycle. Mice were fed Teklad Irradiated
Global 18% Protein Rodent Diet # 2918 ad libitum and allowed ad libitum access
to water via a Lixit system. Bedding was provided by P.J. Murphy (Coarse
SaniChip) and changed weekly during the study. Cotton pads were provided as
enrichment. The room temperature was maintained at 21°C and room humidity
was maintained at 50%. All protocols were approved by University of Kentucky
IACUC.
Genotyping
Mice were genotyped twice using tail tissue. Group allocation was based
on genotyping performed after weaning at postnatal day 28 and again after study
termination to verify genotypes. AT1aR deletion was assayed using forward
primer 5'-AAATGGCCCTTAACTCTTCTACTG-3' and reverse primer 5'ATTAGGAAAGGGAACA GGAAGC-3' covering a neo cassette that disrupts
AT1aR spanning bps 110-635. The neo cassette removed approximately 0.5 kb
and inserted approximately 1 kb of neo gene. AT1aR+/+ generated a 631 bp
product. AT1aR-/- generated a ~1.1 kbp product. Fbn1C1041G/+ was assayed using
forward primer 5'-CTCATCATTTTTGGCCAGTTG-3' and reverse primer 5'GCACTTGATGCACATTCACA-3' covering a single loxP intronic sequence within
intron 24 which should not exist in wild type mice. The protocol used was as
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described by The Jackson Laboratory. Fbn1+/+ generates a 164 bp product.
Fbn1C1041G/+ generates a 212 bp product. Post-termination validation genotyping
was performed by Transnetyx.
Antisense Oligonucleotides
Scrambled control ASO (#549149) and AGT ASO (#109547) were
provided by Ionis Pharmaceuticals. Lyophilized ASOs were diluted in PBS as
recommended by the manufacturer. Mice were randomized to study group using
a random number generator. Two-month-old male Fbn1C1041G/+ mice were
administered control ASO or AGT ASO (80 mg/kg) subcutaneously at day 1 and
3 of study. Mice were maintained on subcutaneous control ASO or AGT ASO (40
mg/kg) every 7 days for the remainder of the study.
Ultrasound Measurements
Ultrasound was performed by standardized protocols that have been as
described previously.(35, 148) Briefly, mice were anesthetized using inhaled
isoflurane (2-3% vol/vol) and maintained at a heart rate of 450-550 beats per
minute during image capture to reduce anesthesia exposure and maintain
consistent heart rate between animals (Somnosuite, Kent Scientific). The order
by which mice were subject to ultrasound was randomized. Ultrasound images
were captured using a Vevo 3100 system with a 40 MHz transducer
(Visualsonics). Images captured were standardized according to two anatomical
landmarks: the innominate artery branch point and aortic valves. The largest
luminal ascending aortic diameter between the sinotubular junction and the
innominate artery were measured in end-diastole over three cardiac cycles by
two independent observers.
Measurement of in situ Aortic Diameters
Mice were terminated by overdose of ketamine:xylazine followed by
cardiac puncture and saline perfusion. The order in which mice were taken down
was randomized. Aortas were dissected away from surrounding tissue and
Optimal Cutting Temperature Compound (Sakura Finetek) was introduced into
the left ventricle to maintain aortic patency. A black plastic sheet was inserted
beneath the aorta and heart to increase contrast and facilitate visualization of
aortic borders. Aortas were imaged using a Nikon SMZ800 stereoscope and
measurements were recorded using NIS-Elements AR 4.51 software (Nikon
Instruments Inc.). Ascending aortic diameters were measured at the largest width
perpendicular to the vessel.
Histology
Mice were ranked according to their ascending aortic diameter by
ultrasound, and the median five per group were selected for histology. Tissue
sections (10 µm) were acquired from the aortic root to the aortic arch at 100 µm
intervals using a cryostat. The section corresponding to a region of maximal
dilation between the sinotubular junction and the arch was analyzed. Elastin
fragmentation was visualized by Verhoeff elastin staining under 20x
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magnification and images from three high powered fields per section were
recorded for analysis. Individual data were represented as the mean of three high
power fields. Fragmentation was defined as the presence of discernable breaks
of continuous elastic lamina. Medial thickness was measured at the greatest
thickness from inner to external elastic laminae in 3 images using NIS-Elements
AR software. Measurements were verified by an independent investigator who
was blinded to sample identification.
AGT Western Blotting
Reducing buffer (Bio-Rad 161-0737 and Sigma M7522) and plasma (0.3
μL) from mice administered control or AGT ASO were heated to 95°C for 5
minutes. Samples were fractionated on an SDS-PAGE gel (10% wt/vol; Bio-Rad
456-8033). Proteins were transferred to a PVDF membrane via Trans-blot
system (Bio-Rad 170-4256). Total proteins were detected by Ponceau S.
Membranes were blocked by milk (5% wt/vol; Bio-Rad 170-6404) in TBS-T (0.1%
wt/vol). Membranes were then incubated with antibodies against total AGT (0.1
μg/mL; IBL 28101) for 1 hour at room temperature then with HRP-conjugated
goat-antirabbit IgG (0.2 μg/mL; Vector Pi-1000). Membranes were developed
with Clarity Max ECL (Bio-Rad 1705064) on a ChemDoc MP system. Blots were
quantified using Bio-Rad CFX software.
Statistics
All animals that met pre-specified inclusion criteria, and were not excluded due to
death by humane endpoint unrelated to aortic disease (fighting, infection), had
cause of death adjudicated by necropsy. Statistical analyses were performed
using SigmaPlot 14.0. Equal variance and normality of data determined whether
non-linear, logarithmic transformation was performed and whether parametric or
non-parametric tests were used. Two-way ANOVA or Student’s t-test was
performed for parametric comparisons; Holm-Sidak was used for post-hoc tests.
Kruskal-Wallis or Rank Sum was performed for non-parametric comparisons with
Dunn’s method for post hoc tests. Data are represented as individual data points,
mean ± SEM, or as box and whisker plots representing median and interquartile
range where applicable.
3.4

Results

Progression of Aortic Dimensions was Sexually Dimorphic in Fbn1C1041G/+ Mice
In initial studies, the progression of aortic diameters over a 12-month
interval was determined in both male and female Fbn1+/+ and Fbn1C1041G/+ mice.
Because TAA in Fbn1C1041G/+ mice has variable pathology within the proximal
thoracic aorta, several parameters were measured (Figure 3.1). This included
the ascending aortic diameter, aortic root diameter, and ascending aortic length.
In Fbn1+/+ mice, there was no statistical difference in the ascending aorta
diameter, aortic root diameter, or ascending aortic length between female and
male at any interval up to 12 months of age (Figure 3.2A, B, C). At one month of
age, aortic root diameters and ascending aortic lengths were increased in both
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male and female Fbn1C1041G/+ mice compared to Fbn1+/+ mice. However, only
male Fbn1C1041G/+ mice exhibited statistically significant ascending aortic dilation
compared to sex-matched littermates at one month of age. Despite differences at
1 month of age in female mice, the subsequent increase in diameter of
ascending aorta and aortic root, and length of the ascending region were not
statistically different between Fbn1+/+ and Fbn1C1041G/+ mice (Figure 3.2D, E, F).
In contrast, male Fbn1C1041G/+ mice had augmented increases in diameters of
ascending aorta and aortic root and ascending aortic length, compared to male
Fbn1+/+ littermates over the course of 12 months. Since female Fbn1C1041G/+ mice
had no significant differences in the progression of aortic dimensions compared
to their wild type littermates, subsequent experiments used predominantly male
mice.
AT1aR Deletion Attenuated Aortic Pathology in Male Fbn1C1041G/+ Mice
To study the effects of AT1aR on aortic dilation in Fbn1C1041G/+ mice,
C1041G/+
Fbn1
mice that were either AT1aR+/+ or AT1aR-/- were generated.
Fbn1C1041G/+ mice were also compared against Fbn1+/+ mice that were also either
AT1aR+/+ or AT1aR-/-. Aortic dimensions were measured using ultrasound images
acquired from a right parasternal view at diastole (Figure 3.3A). Images were
acquired from every mouse at the stated intervals up to 12 months of age, with
no deaths of any cause occurring during the study.
Male Fbn1+/+ mice had modest increases in diameters of the ascending
aorta (Figure 3.3B), aortic root (Figure 3.3C), and lengths of the ascending aorta
(Figure 3.3D) during the course of the 12-month study. These increases were
not significantly different from increases seen in Fbn1+/+ mice that were also
AT1aR-/-. These findings based on the ultrasound measurements were confirmed
at the 12-month interval by direct measurements on in situ aortas (Figure 3.3E,
F).
At 1 month of age, male Fbn1C1041G/+ mice had increased diameters of
ascending aorta and aortic root and lengths of ascending aorta compared to
Fbn1+/+ mice. At this early age, deletion of AT1aR had no effect on aortic
dimensions (Figure 3.4). In Fbn1C1041G/+ mice that were AT1aR+/+, there was a
progressive increase in all 3 aorta dimensions acquired by ultrasound. In
contrast, deletion of AT1aR markedly attenuated the progressive expansion of
these dimensions to rates that were not statistically different from those in
Fbn1+/+ mice (Figure 3.5). As with Fbn1+/+ mice, direct aortic measurements in
situ at 12 months of age confirmed the data acquired by ultrasound. Consistent
with previously published research,(17) body weight and systolic blood pressure
were not correlated with ascending aortic dimensions in mice (Figure 3.6).
Female Fbn1+/+ and Fbn1C1041G/+ mice that were with either AT1aR +/+ or -/were also generated and aortic dimensions measured up to 12 months of age.
As noted above, beyond the initial differences at 1 month of age, progressive
changes in aortic dimensions were not different between Fbn1+/+ and
Fbn1C1041G/+ female mice. The deletion of AT1aR had no effect on the agerelated changes in either group (Figure 3.7, 3.8).
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To determine if AT1aR deletion impacted the structure of the aortic media,
histological characteristics were determined in aortic tissues acquired at 12
months of age. Since the most dramatic differences in changes of dimensions
described above were in the ascending aorta, this region was selected for tissue
characterization using our validated and reproducible method (Figure 3.9).
Ascending aortic tissues from Fbn1+/+ mice had elastic fibers with minimal
fragmentation (Figure 3.10A). Neither the extent of fragmentation nor medial
thickness were altered by the absence of AT1aR in Fbn1+/+ mice (Figure 3.10B,
C). In contrast, Fbn1C1041G/+ x AT1aR+/+ mice had extensive fragmentation of
elastic fibers and marked medial thickening. Deletion of AT1aR in these mice
significantly reduced elastin fragmentation and medial thickening.
Depletion of Plasma AGT Concentrations by AGT ASO Attenuated Aortic
Pathology in Male Fbn1C1041G/+ Mice
We have demonstrated previously that administration of AGT ASO
markedly reduces plasma concentration of AGT and attenuates AngII responses
in mice.(68, 149) Using ASO against the same target as previous publications,
male Fbn1C1041G/+ mice received a loading dose (80 mg/kg) of either AGT or
control ASO on day 1 and day 4 of the study. Starting on day 7, mice received a
maintenance dose (40 mg/kg) every 7 days for 6 months. (Figure 3.11A). Mice
tolerated the ASO well and displayed minimal hepatic and renal toxicity after
administration of loading doses (Figure 3.12) AGT ASO effectively depleted AGT
in plasma (Figure 3.11B).
Aortic dimensions were acquired starting at 2 months of age, and every
month for a further 6 months using the same process described above (Figure
3.11C) with in situ aortic measurements at termination confirming the ultrasound
measurement. (Figure 3.11D). AGT depletion achieved by the ASO
administration led to statistically significant reductions in expansion of diameters
of ascending aorta (Figure 3.11E) and aortic root (Figure 3.11F) and length of
ascending aorta (Figure 3.11G) in male Fbn1C1041G/+ mice.
To determine whether AGT ASO impacted aortic medial structure,
histology was performed on ascending aortic tissue. Consistent with our previous
observation, we detected aortic medial remodeling in 8-month-old male
Fbn1C1041G/+ mice administered control ASO (Figure 3.13A). Compared to male
Fbn1C1041G/+ mice administered control ASO, male Fbn1C1041G/+ mice
administered AGT ASO exhibited less elastin fragmentation and medial
thickening (Figure 3.13B, C).
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3.5

Discussion

Using pharmacological tools to manipulate the renin angiotensin system,
there have been consistent demonstrations that losartan attenuates aortic
pathology in mice with fibrillin-1 manipulations.(64, 74, 76, 83, 86, 150, 151)
However, it has been proposed that losartan may exert these beneficial actions
independent of AT1 receptor antagonism.(74, 83, 86) Additionally, it has been
suggested that AngII may not be responsible for cardiovascular pathology in
mice with genetically manipulated fibrillin-1.(92) However, the present study
demonstrates that both genetic deletion of AT1aR and techniques to reduce
AngII availability led to reduced aortic pathology in Fbn1C1041G/+ mice. These
findings are consistent with ligand activation of AT1aR being the basis for aortic
expansion in fibrillin-1 haploinsufficient mice.
The sequential measurement of aortic dimensions over a protracted
interval in multiple groups required development of a standardized ultrasound
protocol for image acquisition. We have noted previously the variance imparted
by the differences acquiring dimension at systole or diastole.(35) Given that this
excursion can be as much as 0.2 mm, lack of consistency in acquiring data could
have a profound effect on data interpretation. The approach used in this study
also consistently imaged the aorta from the right parasternal view.(34) While this
view is optimal for determining dimensions of the ascending aorta, we
acknowledge that this reduces accuracy of aortic root measurements. In the
present study, there was strenuous adherence to a standardized protocol. In
addition, the measurements acquired from ultrasound images were validated at
termination by direct measurement of aorta in situ. This degree of measurement
validation allows us to not only produce reliable data but also reduces the
variability between sequential measurements.
Since we were not aware of any previous study that defined the effects of
sex on the aortic pathology in Fbn1C1041G/+ mice, the initial studies used both
males and females. The present study demonstrates a striking effect of sex on
the aorta in these mice, with the female Fbn1C1041G/+ mice exhibiting minimal
progression of thoracic aortic expansion compared to sex-matched Fbn1+/+
littermates. In mice with genetic manipulations of Fbn1, there had been only one
study indicating that sexual dimorphism existed in the Fbn1GT8/+ mouse model of
Marfan syndrome.(56) However, sexual dimorphism of the Fbn1GT8/+ mouse was
only defined in the context of pregnancy. In addition to revealing that female
Fbn1C1041G/+ mice resist aortic dilation, we outlined the consequences of this
sexual dimorphism on the role of AT1aR deletion. While the mechanism of this
sexual dimorphism is beyond the scope of the present study, it illustrates the
need for studies to report data on studies in these mice in a sex-specific manner.
Deletion of AT1aR markedly reduced progression of aortic pathology in
male Fbn1C1041G/+ mice. AT1 receptors in mice have two isoforms, AT1aR and
AT1bR, that resulted from chromosomal duplication. While there is strong
sequence homology between the two isoforms, they have different tissue
distribution and different signaling mechanisms. Absence of AT1bR has modest
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effects in vivo, although it is responsible for AngII induced contractions of the
infrarenal mouse aorta.(70, 152) Absence of AT1bR has no effect on AngIIinduced aortopathies.(70) AT1aR deficient mice were initially demonstrated to
have lower blood pressure.(153) However, in agreement with the present study,
there has also been several publications showing no difference in blood pressure
between AT1aR+/+ and -/- mice.(154) While the present study was ongoing, the
genetic deletion of AT1aR was reported in Fbn1 hypomorphic mice. While global
deletion of AT1aR in Fbn1 hypomorphic mice had no significant effect on the
survival, there was decreased aortic expansion in mice that survived to 90
days.(75) This emphasizes the need for further study on the divergent roles of
the renin angiotensin system in aneurysm versus rupture/dissection. The early
acquisition of ultrasound data in this study also illustrated that there are changes
in aortic dimension in the early postnatal interval. Despite the dramatic reduction
of progression of aortic dimensions in AT1aR-/- mice following this postnatal
interval, the absence of AT1aR failed to affect early changes. This is consistent
with temporal-dependent mechanisms of the disease as have been
demonstrated previously in Fbn1 hypomorphic mice.(75)
Others have noted that AT1aR deficiency had no effect on expansion of
the aortic root at 3 and 6 months of age in Fbn1C1041G/+ mice, whereas losartan
had a divergent effect and was able to decrease aortic root expansion in these
mice.(86) The beneficial effects of losartan were attributed to preservation of
endothelial function in an AT1aR independent manner through an alternative
VEGFR2/eNOS pathway. The basis for the disparity relative to the present study
are not clear. Comparisons are hampered by the paucity of data on the protocol
for ultrasound acquisition and on the sex of the mice in each group. Other studies
suggested that losartan’s protective effect may be due to tumor growth factor β
inhibition or AngII receptor type 2 hyperstimulation.(64, 83) However, our data
indicated that blockade of the AT1aR attenuates Marfan syndrome associated
TAA. While the pleotropic effects of losartan may contribute to attenuating
thoracic aortopathies, the present study is consistent with the postulate that its
benefit is due to inhibition of AT1aR activation.
We used an ASO to decrease the synthesis of the unique precursor of all
angiotensin peptides to determine whether AT1aR stimulation in aortopathies
required AngII as a ligand. This approach is advantageous over the more common
mode of reducing AngII production by inhibiting angiotensin-converting enzyme,
which regulates other pathways including the kinin-kallikrein system. Additionally,
the protracted half-life of ASO leads to persistent inhibition of AGT synthesis and
profound reductions in plasma AGT concentrations. Use of this pharmacologic
modality also avoids adverse consequences of genetic deletion of the renin
angiotensin system components. Previous genetic approaches have included the
use of mice with global deficiencies of AGT. However, these mice have several
major developmental abnormalities include poor growth and cardiomyopathy.(155)
Inhibition of AGT synthesis by an ASO reduces plasma concentrations by
approximately 90% in the postnatal phase with no observable toxicity as
demonstrated in the present study and other reports.(68, 156) Therefore, the use
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of ASO to deplete AGT demonstrated the need for the presence of angiotensin
ligands to augment aortic pathology in Fbn1C1041G/+ mice.
In humans, randomized control trials of angiotensin receptor blockers have
yielded mixed results in Marfan syndrome associated TAA, in contrast to the
consistent results that have been generated using mouse models of the
disease.(64, 74, 76, 83, 86, 150, 151) Most of the mouse and human studies have
been performed using losartan, which is characterized by a relatively short half-life
and surmountable antagonism. The deficiencies of this drug were likely to have
been ameliorated in mouse studies by consistent delivery, via osmotic pumps and
diet, leading to a persistent inhibition. AT1 receptor antagonists with enhanced
pharmacological profiles, such as irbesartan and candesartan, would be preferable
to test the role of AT1 receptor inhibition in humans. Indeed, it has been
demonstrated recently that irbesartan significantly attenuated aortic root
expansion in individuals with Marfan syndrome.(63) Conversely, ASO affords
chronic and persistent inhibition of AGT synthesis to effect long term depletion of
angiotensin ligands. These durable effects of ASO enables inhibition of AGT
synthesis to be tested as a possible approach to reduce thoracic aortic dilation in
Marfan syndrome.
Our study provided strong evidence that both AT1aR deletion and AGT depletion
resulted in significant attenuation of aortic dilation and lengthening. These data are
consistent with AngII signaling through AT1aR being necessary for TAA
progression in male Fbn1C1041G/+ mice and that profound and persistent depletion
of either component is sufficient to attenuate TAA. This study enables future
studies to focus on cell types(s) expressing AT1aR that are stimulated to promote
the disease. These studies would give great insight into the role of AT1aR on key
spatial and temporal events during TAA development but would require generation
of cell-specific and lineage traced AT1aR knockouts in a Marfan mouse model.
Collectively, these data indicate that renin angiotensin system blockade holds
promise in treating Marfan syndrome associated TAA when durable inhibition is
achieved. Durable inhibition would encompass use of angiotensin receptor
blockers with long half-lives and unsurmountable modes of inhibition as well as
ASO based approaches.
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Figure 3.1 Regional heterogeneity of TAA in Fbn1C1041G/+ mice
TAAs in one year old Fbn1C1041G/+ mice have a variable phenotype of pathology
location. Examples include aneurysmal presence in; A) ascending aorta only, B)
aortic root only, or C) both segments. Green bar = 1 mm.
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Figure 3.2 TAA in Fbn1C1041G/+ mice is sexually dimorphic
Sequential ultrasound measurements of the A) ascending aorta, B) aortic root,
and C) aortic length in diastole from 1 month to 12 months of age of male and
female Fbn1+/+ and Fbn1C1041G/+ mice. Data represented as change in
dimensions over baseline at 1 month of age of the D) ascending aorta, E) aortic
root, and F) aortic length. * p<0.05 of male Fbn1C1041G/+ versus female
Fbn1C1041G/+ mice; n = 9-15/group.
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Figure 3.3 AT1aR deletion attenuated ascending aortic dilation in male
Fbn1C1041G/+ mice
A) Representative ultrasound images of the thoracic aorta in male AT1aR+/+ x
Fbn1+/+, AT1aR-/- x Fbn1+/+, AT1aR+/+ x Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+
mice. Green bar = 1 mm. Sequential ultrasound measurements of the B)
ascending aorta C) aortic root and D) aortic length. * p<0.05 of AT1aR+/+ x
Fbn1+/+ versus AT1aR+/+ x Fbn1C1041G/+; † p<0.05 of AT1aR+/+ x Fbn1C1041G/+
versus AT1aR-/- x Fbn1C1041G/+; n = 11-15/group. E) Representative in situ images
of the thoracic aorta. F) Measurement of in situ aortic dimensions taken at the
maximal aortic diameter. † p<0.01; ‡ p<0.001; n = 10-15 / group.
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Figure 3.4 Aortic dimensions at 1 month of age and aortic growth in male
mice
Ultrasound measurements of the A) ascending aorta, C) aortic root, and E) aortic
length in diastole at 1 month of age from male AT1aR+/+ x Fbn1+/+, AT1aR-/- x
Fbn1+/+, AT1aR+/+ x Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+ mice. Mean
monthly ascending B) ascending aorta growth, D) aortic root growth, and F)
aortic length growth from 1 month to 12 months in male AT1aR+/+ x Fbn1+/+,
AT1aR-/- x Fbn1+/+, AT1aR+/+ x Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+ mice. *
p<0.05, † p<0.01, ‡ p<0.001; n = 11-15/group.
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Figure 3.5 Growth from 1 month of age in male AT1aR deficient, Fbn1C1041G/+
mice
Data are represented as change in dimensions over the measurement at 1
month of age of the A) ascending aorta, B) aortic root, and C) aortic length. *
p<0.05 of AT1aR+/+ x Fbn1C1041G/+ versus AT1aR-/- x Fbn1C1041G/+; n = 1111/group.
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Figure 3.6 Confounding factors did not contribute to TAA phenotype in
male Fbn1C1041G/+ mice
A) Systolic blood pressure measured by a tail cuff based technique in 12 month
old male mice. * p<0.05, † p<0.01, ‡ p<0.001; n = 5-10/group. B) Sequential
body weight of male mice. C) Correlation between systolic blood pressure and
aortic diameters at 12 months of age between male mice. n = 5-10/group. Black
= AT1aR+/+ x Fbn1+/+, green = AT1aR-/- x Fbn1+/+, red = AT1aR+/+ x Fbn1C1041G/+,
and yellow = AT1aR-/- x Fbn1C1041G/+.
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Figure 3.7 AT1aR deletion had no effect on aortic measurements in female
Fbn1C1041G/+ mice
Sequential ultrasound measurements of the; A) ascending aorta, B) aortic root,
and C) aortic length in diastole from 1 month to 12 months of age of female
AT1aR+/+ x Fbn1+/+, AT1aR-/- x Fbn1+/+, AT1aR+/+ x Fbn1C1041G/+, and AT1aR-/- x
Fbn1C1041G/+ mice. * p<0.05 of AT1aR+/+ x Fbn1+/+ versus AT1aR+/+ x
Fbn1C1041G/+; † p<0.05 of AT1aR+/+ x Fbn1C1041G/+ versus AT1aR-/- x Fbn1C1041G/+;
n = 7-11/group.
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Figure 3.8 Aortic dimensions at 1 month of age and aortic growth in female
mice
Ultrasound measurements of the; A) ascending aorta, C) aortic root, and E)
aortic length in diastole at 1 month of age from female AT1aR+/+ x Fbn1+/+,
AT1aR-/- x Fbn1+/+, AT1aR+/+ x Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+ mice.
Mean monthly ascending B) ascending aorta growth, D) aortic root growth, and
F) aortic length growth from 1 month to 12 months in female AT1aR+/+ x Fbn1+/+,
AT1aR-/- x Fbn1+/+, AT1aR+/+ x Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+ mice. *
p<0.05, † p<0.01, ‡ p<0.001; n = 7-11/group.
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Figure 3.9 Generation of ascending aortic sections to measure elastin
fragmentation and medial thickening
A) Generation of serial sections of ascending aortas used for histology. (blue
lines) Three high powered fields / section were imaged and quantified per
biological replicate. (red boxes) B) Quantification of elastin fragmentation
(triangle) and medial thickening (inverted double arrow) by two independent
observers demonstrated good agreement in both measures via Bland-Altman
analysis. C) Low magnification images of aortic sections stained with Verhoeff
elastin stain in 12 month old male AT1aR+/+ x Fbn1+/+, AT1aR-/- x Fbn1+/+,
AT1aR+/+ x Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+ mice. D) Low magnification
images of aortic sections stained with Verhoeff elastin stain in 8 month old male
Fbn1C1041G/+ mice after 6 months of control ASO or AGT ASO.
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Figure 3.10 AT1aR deletion attenuated medial remodeling in male
Fbn1C1041G/+ mice
A) Representative images of Verhoeff’s elastin staining in ascending aortic
sections from male AT1aR+/+ x Fbn1+/+, AT1aR-/- x Fbn1+/+, AT1aR+/+ x
Fbn1C1041G/+, and AT1aR-/- x Fbn1C1041G/+ mice. Green bar = 100 μm. B) Number
of breaks per high powered field detected in aortic sections. C) Medial thickness
as measured by the distance between the inner elastic lamina and external
elastic lamina in aortic sections. * p<0.05, ‡ p<0.001; n = 5/group.
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Figure 3.11 AGT ASOs depleted AGT and attenuated TAA in male
Fbn1C1041G/+ mice
A) Study design and administration schedule of ASOs in male Fbn1C1041G/+ mice.
A loading dose of control ASO or AGT ASO (80 mg/kg) was administered day 1
and 4 of study. Maintenance doses of control ASO or AGT ASO (40 mg/kg) was
administered every 7 days. B) Western blot of plasma AGT and total plasma
protein in 8 month old male Fbn1C1041G/+ mice administered either control ASO or
AGT ASOs. Blot represents one of two experiments. ‡ p<0.001; n = 6/group.
Representative C) ultrasound and D) in situ images of aortas from 8 month old
Fbn1C1041G/+ mice administered either control ASO or AGT ASO. Green bar = 1
mm. Sequential ultrasound measurements of the E) ascending aorta, F) aortic
root, and G) aortic length in diastole from 2 months to 8 months of age in male
Fbn1C1041G/+ mice dosed with either control ASO or AGT ASO. * p<0.05, †
p<0.01, ‡ p<0.001; n = 8-10/group.

60

Figure 3.12 AGT ASOs have low toxicity and effectively reduce circulating
AGT
Plasma concentrations of; A) albumin, B) alanine transaminase (AST), C)
aspartate aminotransferase (ALT), D) total bilirubin E) blood urea nitrogen (BUN)
in mice administered either PBS, AGT ASO (40 mg/kg), or AGT ASO (80 mg/kg)
at days 1 and 4. Plasma was taken at days 3 and 7. n = 4/group. F) Plasma AGT
concentrations at days 3 and 7 detected by Western blotting after AGT ASO was
administered at days 1 and 4.
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Figure 3.13 AGT ASOs attenuated medial remodeling in male Fbn1C1041G/+
mice
A) Representative images of Verhoeff’s elastin staining in aortic sections from
male Fbn1C1041G/+ mice administered either control ASO or AGT ASO for 6
months. Green bar = 100 μm. B) Number of breaks per high powered field
detected in aortic sections. C) Medial thickness as measured by the distance
between the inner elastic lamina and external elastic lamina in aortic sections. †
p<0.01, ‡ p<0.001; n = 5/group.
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CHAPTER 4. ENDOGENOUS SEX HORMONE REMOVAL ATTENUATES ACQUIRED
THORACIC AORTIC ANEURYSMS
This chapter is based on a publication in preparation titled “Endogenous Sex
Hormone Removal Attenuates Acquired Thoracic Aortic Aneurysms” detailing
findings that endogenous sex hormone removal attenuates spontaneous but not
syndromic thoracic aortic aneurysms.
4.1

Synopsis

Objective:
Thoracic aortic aneurysm (TAA) of various etiologies have been shown to
be sexually dimorphic. In general, sexually mature females have higher levels of
circulating estrogens and males have higher levels of circulating androgens.
These endogenous sex hormones may remodel tissue. Here, we investigate the
impact of removing endogenous sex hormones on TAA development in the
angiotensin II (AngII)-infused mouse model of acquired TAA and the fibrillin-1
hypomorphic (FBN1mgR/mgR) mouse model of syndromic TAA.
Approach and Results:
In situ aortic diameter measurements demonstrated that both male AngIIinfused and FBN1mgR/mgR mice exhibited increased aortic dimensions compared
to their female counterparts. Ovariectomy in female and orchiectomy in male
mice was employed to remove endogenous estrogen and testosterone,
respectively. In AngII-infused females, ovariectomy exacerbated ascending aortic
dilation. In AngII infused males, orchiectomy abrogated aortic root and ascending
aortic dilation. Gonadectomy failed to modulate established TAA in FBN1mgR/mgR
mice. AngII-induced ascending aortic elastin fragmentation was exacerbated in
ovariectomized females and attenuated in orchiectomized males. There was no
effect of gonadectomy on FBN1mgR/mgR mice with established TAA. Furthermore,
expression of α-smooth muscle actin in the aortic media were altered by removal
of endogenous sex hormones.
Conclusions:
AngII-induced TAA in mice was exacerbated by ovariectomy of female
mice and ameliorated by orchiectomy of male mice. This effect was not seen in
female or male mice with established TAA. These data indicate that endogenous
estrogens are protective against and endogenous androgens are detrimental to
the development of TAA but may have limited effect on reversing established,
syndromic TAA.
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4.2

Introduction

Previous observational studies in patients with Marfan syndrome
demonstrated that males displayed greater aortic dilation and were more likely to
require aortic repair compared to their female counterparts.(157) However,
observational studies in human TAAs reveal that female patients have worse
outcomes associated with increased aortic stiffness. (158) It is unclear how
sexual dimorphism in TAA occurs and why females resist TAA while males are
susceptible to TAA. However, females generally have higher concentrations of
circulating estrogens and males generally have higher concentrations of
circulating androgens. In fact, changes in 17β-estradiol during pregnancy impact
Marfan syndrome associated TAA.(56) Thus differences in sex hormones may
contribute to sexual dimorphism of TAAs.
To study both acquired and syndromic TAA, we utilized two models with
divergent etiologies. First described by our group, the AngII infusion mouse
model is a widely used model of acquired TAA.(37) TAA in this mouse model
occurs through the action of AngII on AT1a receptors.(28) The FBN1mgR/mgR
Marfan syndrome mouse model aggressively develops TAA early in the perinatal period and exhibits death by aortic rupture. (12) Previous work in LDL
receptor-/- x AngII-induced abdominal aortic aneurysms revealed that having a
female sex chromosome complement and exposure to endogenous female sex
hormone attenuates initiation, progression, and extent of abdominal aortic
aneurysms. (159-161) As both the AngII-induced and FBN1mgR/mgR mouse
models occur without underlying hypercholesteremia and hyperlipidemia, it is
unclear if removal of endogenous sex hormones affects the thoracic aorta in the
same manner as the abdominal aorta.
Based on the literature, we hypothesized that sexual dimorphism exists in
mouse models of acquired and syndromic TAA. Furthermore, we hypothesized
that female mice were protected from TAA due to their exposure to estrogens
and that males were more susceptible to TAA due to their exposure to
androgens. Based on our previous work, we hypothesized that these changes
were also reflected in degradation or preservation of aortic medial structure. To
test these hypotheses, we first measured aortic diameters in male and female
mice of both AngII-infused and FBN1mgR/mgR mice compared to natural sexual
dimorphism in non-TAA, vehicle treated or wild type littermates. We then
investigated the effect of removing endogenous sex hormones, before sexual
maturity, on TAA development and progression. In addition to measuring aortic
dilatation, we also characterized the medial structure of the aorta to determine if
removing endogenous sex hormones directly impacted aortic tissue structure and
function by preserving elastin structure and vascular smooth muscle cell
contractile phenotype.
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4.3

Methods

Mice

Female and male C57BL/6J (stock #000664) mice were obtained from
The Jackson Laboratory (Bar Harbor, ME). FBN1mgR/mgR mice (stock #005704)
were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred in
house. Female and male FBN1mgR/mgR mice and their wild type littermates were
generated by F1 cross of female and male FBN1mgR/+ mice. To induce acquired
TAA, C57BL/6J mice were infused with 1000ng/kg/min AngII (Bachem H-1705,
Lot 1046885) for 28 days by osmotic minipump (Alzet 1004, Lot 10217-08). Mice
were housed up to 5/cage and maintained on a 14:10 light:dark cycle. Mice were
fed Teklad Irradiated Global 18% Protein Rodent Diet # 2918 ad libidum and
allowed ad libidum access to water via a Lixit system. Bedding was provided by
P.J. Murphy (Coarse SaniChip) and changed weekly during the study.
Shreddable cotton pads were provided as enrichment. The room temperature
was set at 22°C throughout the study. The room was also set at 50% humidity.
All mice survived to end of study. All protocols were approved by the University
of Kentucky IACUC.
Gonadectomy
Gonadectomies were performed at 6 weeks of age in AngII TAA studies
and 8 weeks of age in FBN1mgR/mgR mice according to established protocols.(159,
161) Mice were allowed to recover for two weeks before AngII infusion. Post
termination, female uteri and male seminiferous vesicles were dissected free and
preserved in 10% formalin. Remaining gonads were weighed.
Ultrasound measurements
Mice were anesthetized and maintained at a heart rate of 450-550 beats
per minute. Ultrasound images were captured using a Vevo 3100 system with a
40 MHz transducer according to published protocols.(34, 134) Images captured
were standardized according to two anatomical landmarks: the innominate artery
branch point and aortic valves. The largest luminal ascending aortic diameter
between the sinotubular junction and the innominate artery were measured in
mid-systole and end-diastole by two blinded, independent observers.
Histology
The three ascending aortas per group, as determined by the group
median aortic diameter, were selected and fresh frozen sections were generated.
Tissue sections (10 µm) were generated from the aortic root to the aortic arch at
100 µm intervals. The section corresponding to the region of largest dilation
between the sinotubular junction and the arch were analyzed. Briefly, elastin was
visualized by Verhoeff elastin staining under 20x magnification. Three images per
section were taken. Fragmentation was defined as the presence of discernable
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breaks of continuous elastin lamina. Elastin breaks per high powered field were
counted. Medial thickening was measured using NIS-Elements AR software
(Nikon). Measurements were verified by an independent investigator who was
blinded to the sample group. To detect α-smooth muscle actin, slides were fixed
with acetone for 15 minutes at room temperature; blocked with non-immune goat
serum (15µL/mL, sigma G9023); incubated with anti α-smooth muscle actin
(10µg/mL, abcam #ab5694) for 15 minutes at 40°C; incubated with biotinylated
goat anti rabbit IgG (2 µg/mL, vector #BA1000) for 15 minutes at 40°C;
developed with AEC (Vector #PK6100 and #SK4205).
Statistics
Mice were randomized to sham or gonadectomy and to saline or AngII
pump. FBN1mgR/mgR mice were randomly housed with their wild type littermates.
Primary data were assessed and then verified by an independent observer
blinded to group. Statistical analyses were performed using SigmaPlot. Equal
variance and normality of data determined whether parametric, non-linear
transformation followed by parametric, or non-parametric tests were used.
Two-way ANOVA was performed and Holm-Sidak post-hoc test was used. Data
are represented as individual data points, mean ± SEM, or median with
interquartile range as appropriate.
4.4

Results

Sexual dimorphism is observed in both AngII-induced and FBN1mgR/mgR mouse
models of thoracic aortic aneurysms.
We first noticed sexual dimorphism in our thoracic aortic aneurysm mouse
models due to an inability to elicit severe aortic dilation in female mice. Thus, we
investigated the aortic phenotype of female and male littermates to quantify the
degree of sexual dimorphism in our TAA mouse models.
To determine if sexual dimorphism existed in an acquired model of TAA,
we infused AngII into male and female C57BL/6J mice for 28 days. At the end of
28 days, we dissected the aortas in situ and measured the dimensions of the
ascending aorta. (Figure 4.1). Male mice exhibited greater thoracic aortic dilation
after AngII infusion compared to their female littermates. (Female = 1.42 ± 0.04
mm, male = 1.70 ± 0.05 mm; p < 0.001) Interestingly, saline infused mice did not
exhibit sexual dimorphism. (Female = 1.22 ± 0.04 mm, male = 1.35 ± 0.04 mm; p
= 0.052). During this study, 1/11 male AngII-infused mice expired due to aortic
rupture. Cause of death verified by necropsy; all others survived to study
termination. (Figure 4.1)
Next, to determine if sexual dimorphism existed in a syndromic model of
TAA, we generated female and male FBN1mgR/mgR littermates and measured their
ascending aortic dimension at 120 days. (Figure 4.1). Survivors were terminated
and ex vivo aortic diameters were measured. Male FBN1mgR/mgR mice exhibited
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greater thoracic aortic dilation compared to their female littermates. (Female =
1.54 ± 0.09 mm, male = 1.97 ± 0.0 8mm; p = 0.008) Wild type mice did not
exhibit sexual dimorphism. (Female = 1.18 ± 0.09 mm, male = 1.15 ± 0.07 mm; p
= 0.81) (Figure 4.1) 6/21 male FBN1mgR/mgR mice and 3/18 female FBN1mgR/mgR
mice died due to TAA rupture. (Figure 4.1)
Removal of endogenous sex hormones modulates AngII induced acquired
thoracic aortic aneurysm model.
As endogenous sex hormones play a role in aortic remodeling, we
investigated the effect of sex hormone removal in the AngII-induced acquired
thoracic aortic aneurysm model. We performed gonadectomy of male and female
C57BL/6J at 8 weeks of age, allowed two weeks to recover, then induced TAA by
AngII-infusion for 28 days. (Figure 4.2) Ovariectomy of female mice and
orchiectomy of male mice reduced levels of endogenous sex hormones, leading
to secondary sex organ atrophy. (Figure 4.3) We then used high frequency
ultrasound to measure the ascending aorta and aortic root dimensions in vivo of
female and male mice. (Figure 4.2) Confounding features such as blood
pressure and body weight did not correlate with aortic diameters in either female
or male mice infused with AngII. (Figure 4.4 and 4.5)
Gonadectomy exacerbated TAA in female mice and attenuated TAA in
male mice. Female mice infused with AngII and subjected to sham surgery
showed significant dilation after 4 weeks of AngII (Ascending aorta: Sham Saline
= 1.16 ± 0.03 mm versus Sham AngII = 1.30 ± 0.03 mm; p = 0.004),
demonstrating that TAA was established. However, dilation was increased in
ovariectomized female mice (Ascending aorta: OVX Saline = 1.23 ± 0.03 mm
versus OVX AngII = 1.42 ± 0.03 mm; p<0.001). Ovariectomy of AngII infused
female mice exacerbated ascending aortic dilation (p = 0.007). (Figure 4.2) Male
mice subject to sham surgery were also susceptible to ascending aortic dilation
after AngII infusion and showed significant dilation after 4 weeks of AngII
(Ascending aorta: Sham Saline = 1.27 ± 0.04 mm versus Sham AngII = 1.53 ±
0.04 mm; p<0.001). However, ascending aortic dilation was not seen in
orchiectomized males infused with AngII (Ascending aorta: ORCH Saline = 1.27
± 0.04 mm versus ORCH AngII = 1.36 ± 0.04 mm; p = 0.12). Orchiectomized
males infused with AngII demonstrated attenuated ascending aortic dilation (p =
0.004). (Figure 4.2)
Interestingly, both sham and ovariectomized female mice infused with
AngII exhibited aortic root dilation (Sham Saline = 1.43 ± 0.03 mm versus Sham
AngII = 1.52 ± 0.03 mm; p<0.05; OVX Saline = 1.43 ± 0.04 mm versus OVX
AngII = 1.59 ± 0.04 mm; p = 0.004). However, ovariectomy did not exacerbate
aortic root dilation. (Figure 4.2) Conversely, orchiectomy attenuated aortic root
dilation in male AngII infused mice (Aortic root: ORCH Saline = 1.40 ± 0.05 mm
versus ORCH AngII = 1.54 ± 0.05 mm; p = 0.07). (Figure 4.2) During the course
of study, one orchiectomized male mice implanted with a miniosmotic pump
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delivering AngII died due to rupture of the abdominal aorta and was excluded
from analysis of thoracic aortic aneurysms according to pre-specified exclusion
criteria.
Removal of endogenous sex hormones in FBN1mgR/mgR mice
To determine if gonadectomy affects syndromic TAA, we performed
gonadectomy of female and male FBN1mgR/mgR mice. Gonadectomies were
performed at 8 weeks of age, before sexual maturity but after TAA was
established. Aortic dimensions were measured 4 weeks later by high frequency
ultrasound. (Figure 4.6)
Ovariectomy did not exacerbate ascending aortic dilation in female
FBN1mgR/mgR mice (Sham = 1.92 IQR 0.41 mm, OVX = 2.13 IQR 0.38 mm; p =
1.0). Orchiectomy did not attenuate aortic dilation in male FBN1mgR/mgR mice
(Sham = 2.40 IQR 0.40 mm, ORCH = 2.12 IQR 0.63 mm; p = 1.0). (Figure 4.6)
Similarly, aortic root dimensions were not altered by gonadectomy in female
(Sham = 2.41 IQR 0.28 mm, OVX = 2.13 IQR 0.37 mm; p = 1.0) or male (Sham =
2.44 IQR 0.21 mm, ORCH = 2.50 IQR 0.68 mm; p = 1.0) FBN1mgR/mgR mice.
(Figure 4.6) During the course of study, one sham operated female FBN1mgR/mgR
mouse died of TAA rupture and two orchiectomized female FBN1mgR/mgR mice
died with no evidence of TAA rupture. Additionally, one male sham operated and
one male orchiectomized FBN1mgR/mgR mouse showed evidence of TAA rupture.
These mice were excluded from analysis of in vivo thoracic aortic diameters by
ultrasound according to pre-specified analysis criteria.
Gonadectomy modulates AngII-induced medial remodeling.
TAA is associated with loss of extracellular matrix structure. To determine
if gonadectomy modulates remodeling of the extracellular matrix in the ascending
aorta during TAA, we sectioned and stained ascending aortas for elastin.
First, we measured fragmentation of the elastic lamina in female and male
AngII infused mice. (Figure 4.7) Female mice subject to sham surgery did not
exhibit increased elastin fragmentation after AngII infusion (Sham Saline = 0.6 ±
0.5 breaks/HPF, Sham AngII = 1.6 ± 0.5 breaks/HPF; p = 0.2). However, female
mice subject to OVX exhibited increased elastin fragmentation after AngII
infusion (OVX Saline = 0.4 ± 0.5 breaks/HPF, OVX AngII = 3.0 ± 0.5 breaks/HPF;
p = 0.009). (Figure 4.7) Male mice subject to sham surgery exhibited increased
elastin fragmentation after AngII infusion (Sham Saline = 0.7 ± 0.7 breaks/HPF,
Sham AngII = 4.7 ± 0.7 breaks/HPF; p = 0.003). Male mice subject to ORCH did
not exhibit increased elastin fragmentation after AngII infusion (ORCH Saline =
0.1 ± 0.7 breaks/HPF, ORCH AngII = 1.7 ± 0.7 breaks/HPF; p = 0.1). AngII
induced elastin fragmentation in male mice was attenuated by orchiectomy (p =
0.02). (Figure 4.7)
Next, we measured fragmentation of the elastic lamina in female and male
mgR/mgR
FBN1
mice. (Figure 4.7) OVX and ORCH did not have a significant effect
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on elastin fragmentation in female (Sham = 5.8 ± 1.0 breaks/HPF, OVX = 6.4 ±
1.0 breaks/HPF; p = 0.63) and male (Sham = 9.1 ± 0.9 breaks/HPF, ORCH = 7.4
± 0.9 breaks/HPF; p = 0.24) FBN1mgR/mgR mice. (Figure 4.7)
TAA is associated with vascular smooth muscle cell dysfunction and loss
of contractile phenotype. Staining was concurrently performed with negative
controls to demonstrate specificity. (Figure 4.8) To determine if gonadectomy
altered cellular residents of the aortic media, ascending aortic sections were
stained for α-smooth muscle actin to detect contractile smooth muscle cells.
(Figure 4.9)
4.5

Discussion

These findings give strong evidence that removal of endogenous sex
hormones can modulate AngII-induced acquired TAA. This study suggests that
estrogens are protective against development of acquired thoracic aortic
aneurysms and androgens exacerbate acquired thoracic aortic aneurysms.
However, the effect of sex hormones may be limited in established, syndromic
TAAs.
Divergent results seen in the AngII-infused model of acquired TAA and the
mgR/mgR
FBN1
model of syndromic TAA can be explained by the differences in TAA
pathogenesis. Because we detected sexual dimorphism in both models,
gonadectomies were performed at 8 weeks of age in both TAA models to
attenuate exposure to sex hormones following sexual maturity. The AngIIinfusion mouse model develops TAA in normolipidemic conditions and
independent of blood pressure changes.(28, 37) Aortic pathology can be
detected as early as 3 days after AngII-infusion but do not start unless AngII is
infused. However, gonadectomies were performed before AngII was infused and
before TAA developed. Thus, both initial and progressive TAA was affected.
Conversely, FBN1mgR/mgR mice exhibit rapid dilation and death by aortic rupture
early in life. We chose this model due to its rapid TAA development. By 8 weeks
of age, approximately 10% of male FBN1mgR/mgR mice expired due to TAA
rupture. Gonadectomies were performed at a timepoint when FBN1mgR/mgR mice
normally exhibited TAA. Thus, sex hormone removal would only impact
progressive TAA with minimal impact on dilation occurring before 8 weeks of
age. The severity of TAA coupled with a short follow-up period in FBN1mgR/mgR
mice limits interpretation of the effect of sex hormones in syndromic TAA. To
address these limitations, future experiments should investigate the effect of
gonadectomy in the milder FBN1 C1041G/+ or GT8/+ models to allow
measurement over a longer course.(11, 52)
While this study revealed that gonadectomy alters acquired TAA, the
aortic targets of sex hormones are unknown. One possibility is that removal of
endogenous sex hormones directly alters the renin angiotensin system.
However, this study did not test components of the renin angiotensin system.
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This is due to a lack of validated reagents able to detect components of the renin
angiotensin system such as tissue angiotensin receptor levels.(162, 163) In fact,
several custom anti-angiotensin receptor antibodies generated by our group
failed to show specificity. (118) Another possibility is that sex hormone removal
impacts renin angiotensin system independent processes. A study of the effects
of gonadectomy in AngII and hyperlipidemia induced abdominal aortic
aneurysms revealed a myriad of changes in the aortic tissue.(161) However, it is
unclear which of these targets contribute to the disease process or are merely
correlative. Future studies may make use of transcriptomic or proteomic
techniques to elucidate differentially regulated genes. Ultimately, we do not
advocate gonadectomy of male patients with TAA. However, future research may
reveal the molecular mechanism on how estrogens protect against TAA and
androgens exacerbate TAA. We hope that this will lead to effective therapies for
patients of both sexes.
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Figure 4.1 Sexual dimorphism occurs in both acquired and syndromic
mouse models of thoracic aortic aneurysms
A) Representative images of in situ ascending aortas from female and male mice
infused with either saline or AngII for 28 days. Green bar = 1 mm. B) In situ
dimensions of ascending aortas from female and male mice infused with either
saline or AngII for 28 days. n = 9-10/group. *p<0.01, †p<0.001. C) Survival
curves of female and male mice infused with either saline or AngII for 28 days.
1/11 male mice infused with AngII died due to TAA rupture at day 27. D)
Representative images of in situ ascending aortas from female and male
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FBN1mgR/mgR mice at 16 weeks of age. Green bar = 1 mm. E) In situ dimensions
of ascending aortas from female and male FBN1mgR/mgR mice at 16 weeks of age.
n = 6-8/group. F) Survival curves of female and male FBN1mgR/mgR mice at 16
weeks of age aggregated from four separate cohorts. n = 16-21/group. *p<0.01,
†p<0.001.
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Figure 4.2 Gonadectomy modulated ascending aortic and aortic root
dimensions in AngII-infused female and male mice
A) Study design to investigate sex hormone removal on AngII-induced model of
acquired TAA. Representative diastolic ultrasound images of B) female and C)
male mice subjected to castration or sham surgery and implanted with
miniosmotic pump delivering saline or AngII. Green bar = 1 mm. Ascending aortic
diameters measured by ultrasound in D) female and E) male mice. Aortic root
diameters measured by ultrasound in F) female and G) male mice. n = 811/group. *p<0.05 †p<0.01 ‡p<0.001.
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Figure 4.3 Atrophy of sex responsive organs after gonadectomy of female
and male AngII-infused mice
Representative images of A) uteri from female mice after sham or ovariectomy
and B) testes and seminiferous vesicles from male mice after sham or
orchiectomy. Gonad weight of C) female and D) male mice after gonadectomy
and 28 day infusion of either saline or AngII. n = 8-11/group. *p<0.05 †p<0.01
‡p<0.001.
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Figure 4.4 Systolic blood pressure was not altered by gonadectomy and did
not correlate with aortic diameter
Systolic blood pressure was not significantly different between groups in A)
female or B) male mice. Systolic blood pressure was not significantly correlated
with aortic diameter in C) female or D) male mice. n = 8-11/group
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Figure 4.5 Body weight of mice was not altered by gonadectomy
Body weights of A) female and B) male AngII-infused mice and their wildtype
littermates subject to sham or gonadectomy were not significantly different
between groups at the end of study. Gonadectomy was performed 2 weeks prior
to study (blue arrow), pump implantation (red arrow). Body weights of C) female
and D) male FBN1mgR/mgR mice subject to sham or gonadectomy were not
significantly different between groups at the end of study.
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Figure 4.6 Gonadectomy did not alter aortic dilation after 4 weeks in
FBN1mgR/mgR mice
A) Study design to investigate sex hormone removal on FBN1mgR/mgR model of
syndromic TAA. Representative diastolic ultrasound images of B) female and C)
male FBN1mgR/mgR mice subjected to castration or sham surgery. Ascending
aortic diameters measured by ultrasound in D) female and E) male mice. Aortic
root diameters measured by ultrasound in F) female and G) male mice. n = 4-8 /
group. *p<0.001.
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Figure 4.7 Gonadectomy modulated elastin fragmentation in ascending
aorta of male and female mice
Representative images of ascending aortic sections from A) female and B) male
AngII-infused mice stained with Verhoeff elastin stain demonstrating aortic elastin
lamina structure and medial thickness. Quantification of number of elastin breaks
per high powered field in C) female and D) male AngII-infused mice. n = 3
mice/group. *p<0.05, †p<0.01. Representative images of ascending aortic
sections from E) female and F) male FBN1mgR/mgR mice stained with Verhoeff
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elastin stain demonstrating aortic elastin lamina structure and medial thickness.
Quantification of number of elastin breaks per high powered field in G) female
and H) male FBN1mgR/mgR mice. n = 3 mice/group. †p<0.01, ‡p<0.001.
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Figure 4.8 Controls for α-smooth muscle actin immunostaining
Negative controls for α-smooth muscle actin include preimmune IgG (Rabbit IgG,
Sigma, I8140), no primary, and no secondary control performed concurrently.
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Figure 4.9 Gonadectomy modulates aortic medial expression of contractile
smooth muscle markers in ascending aorta of AngII-infused male mice
Staining of α-smooth muscle actin in the ascending aorta of A) female and B)
male mice demonstrated that AngII infusion led to areas of medial smooth
muscle loss. This was not altered by ovariectomy of female mice and attenuated
by orchiectomy of male mice. Staining of α-smooth muscle actin in the ascending
aorta of C) female and D) male FBN1mgR/mgR mice shows no difference after
gonadectomy in females or males.

81

CHAPTER 5. S100A4-CRE MEDIATED EXCISION OF AT1A RECEPTORS ATTENUATES
SPONTANEOUS BUT NOT SYNDROMIC AORTIC ANEURYSMS IN MICE
This chapter is based on a publication in process titled “S100A4-Cre Mediated
Excision of AT1a Receptors Attenuates AngII-induced but not FBN1C1041G/+
Associated Aortic Aneurysms” detailing findings of the effect of fibroblast specific
deletion of AT1aR on aortopathies.
5.1

Synopsis

Objective:
Thoracic aortic aneurysms (TAA) and aortopathies can have either
spontaneous or syndromic etiologies. In general, inhibition of the angiotensin II
(AngII) receptor type 1a (AT1aR) attenuates TAA of various etiologies. While this
implies that AT1aR stimulation is responsible for TAA, the cell type where AT1aR
become stimulated in TAA formation is unknown. Here, we generated fibroblast
specific deletion of AT1aR and measured TAA development in an AngII-induced
mouse model of spontaneous TAA and in the Fbn1C1041G/+ mouse model of
syndromic TAA.
Approach and Results:
Fibroblast specific deletion of AT1aR was accomplished by breeding mice
expressing Cre under control of the S100A4 promoter (S100A4-Cre) to AT1a
receptor floxed mice. Lineage tracing experiments demonstrated that S100A4Cre was active in fibroblast rich organs and the aorta but not fibroblast poor
organs. Aortic cross sections from S100A4-Cre +/0 ROSA26-LacZ mice infused
with either saline or AngII demonstrated that AngII infusion increased the number
of LacZ traced cells in aortic media. LDL receptor -/- mice with depletion of AT1a
receptors was used to assess spontaneous TAA and atherosclerosis. Eight week
old, male, littermates were fed a fat-enriched diet for 1 week before and during
AngII infusion for 28 days. AngII-induced expansion of ascending aorta area and
abdominal aortic width were attenuated significantly in Cre+/0 mice. However,
there was no significant difference in AngII-augmented atherosclerosis. S100A4Cre driven deletion of AT1aR failed to modulate ascending aorta and aortic root
dilation in Fbn1C1041G/+ mice.
Conclusions:
Fibroblast specific deletion of AT1aR had divergent effects on
spontaneous and syndromic TAA. Additionally, AT1aR deletion failed to
attenuate atherosclerosis. This indicates that the action of AT1aR in TAA
development is heterogenous in aortopathies of different etiologies.
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5.2

Introduction

Fibroblasts are a prominent cell type in the adventitia that have been
proposed to be active participants in aortic aneurysms and atherosclerosis.
During aneurysm formation, adventitial thickening and inflammation are key
histological hallmarks seen in disease. (17, 100) Fibroblasts may play a key role
in aortic remodeling during aortopathy.
Based on our own data as well as other publications, genetic targeting of
AT1 receptors, or pharmacological inhibition by administration of an antagonist,
losartan, ablated development of AngII-induced aortic aneurysms and
atherosclerosis as well as TAA in male Fbn1C1041G/+ mice. (64) In male
Fbn1C1041G/+ mice, AT1aR is activated in a ligand dependent manner during TAA
development. However, the site of action of AT1aR is unknown. Previous studies
deleted AT1a receptors in specific cellular subpopulations of the aortic vessel
wall using AT1a receptor floxed mice. Subpopulations tested include smooth
muscle residents of the aortic media and endothelial cell residents of the aortic
intima. Unexpectedly, deletion of AT1a receptors in smooth muscle cells had no
effect on AngII-induced aortic pathologies or atherosclerosis. (118, 132, 164)
AT1a receptors deleted in endothelial cells have resulted in none or minimal
effects on aortic aneurysms and atherosclerosis. (118) In addition to AngIIinfusion models, deletion of AT1a receptors in smooth muscle and endothelium
also had minimal effects on aortic aneurysms in the genetic fibrilin1 hypomorphic
models of the disease. (75) This model had been previously shown to respond to
pharmacologic AT1 receptor inhibition.(74) Therefore, despite the profound
effects of global AT1a receptor deletion and inhibition on vascular diseases, the
cell type stimulated by AngII necessary to promote these diseases has not been
identified.
Therefore, to determine the cell type responsible for AT1aR induced
aortopathies, we tested the hypothesis that fibroblast specific deletion of AT1aR
attenuated both spontaneous and syndromic aortopathy. First we determined the
specificity of the S100A4-Cre through lineage tracing in fibroblast rich and
fibroblast poor organs. Interestingly, we observed that the traced population in
the aorta expanded after AngII infusion. Next, we observed that S100A4-Cre
mediated AT1a receptor deletion attenuated AngII-induced TAA and AAA but did
not attenuate atherosclerosis. Finally, we observed that S100A4-Cre mediated
AT1a receptor deletion failed to attenuated TAA in Fbn1C1041G/+ mice. This
indicates that the site of action of AT1aR in aortopathies are heterogenous and
specific to each disease process.
5.3

Methods

Mice
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AT1a receptor floxed mice were developed by InGenious Targeting, Inc.
(Ronkonkoma, NY) using a C57BL/6 embryonic stem cell line and are now
available at The Jackson Laboratory (C57BL/6N - Agtr1atm1Uky/J; stock #
016211). S100A4-Cre [BALB/c-Tg(S100a4-cre)1Egn/YunkJ; stock #: 012641)] to
induce fibroblast-specific deletion, ROSA26-LacZ [B6.129S4Gt(ROSA)26Sortm1Sor/J; stock # 003474] for lineage tracing, and LDL receptor -/(B6;129S7-Ldlrtm1Her/J; stock # 002077) mice for inducing hypercholesteremia,
and Fbn1C1041G/+ (stock #012885) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were bred by the following breeding harems:
male S100A4-Cre hemizygous (+/0) x AT1a receptor floxed x LDL receptor -/- to
female AT1a receptor floxed x LDL receptor -/- mice; male S100A4-Cre to female
ROSA26-LacZ; male S100A4-Cre hemizygous (+/0) x AT1a receptor floxed x
female AT1a receptor floxed x Fbn1C1041G/+ mice.
Mice were housed in ventilated cages with negative air pressure
(Allentown Inc.; Allentown, NJ). Drinking water filtered by reverse osmosis and
normal mouse diet (Global 18% protein rodent diet; Diet # 2918; Harlan Teklad;
Madison, WI) were provided ad libitum. Rooms were set with light/dark cycles
(14 hr, 10 hr), and temperature (20-23oC) and humidity (50-60%) controlled.
The studies followed the recommendations of The Guide for the Care and
Use of Laboratory Animals (National Institutes of Health). All procedures were
approved by the University of Kentucky’s Institutional Animal Care and Use
Committee (Protocol # 2006-0009). Necropsies were performed on mice within
12 hours of death.
Detection of β-galactosidase expression during S100A4-Cre excision
Male S100A4-Cre +/0 x ROSA26 mice were infused with saline or AngII
(1,000 ng/kg/min; N=3-6/group) for 28 days. After termination and
exsanguination, aortas were flushed with saline and then perfused with low
melting point agarose containing green dye by introducing a 23 gauge needle
attached to a 1 ml syringe filled with the agarose into the ventricle of the heart.
For sections of ascending aorta, the upper fourth of the heart was left on the
aorta and the aorta was severed 3 mm distal to the common carotid. The
descending aorta sections started 3 mm below the common carotid. The
abdominal aortic sections started 3 mm above the right renal branch. These
three regions of aorta were placed in OCT, frozen and sectioned on a cryostat.
Tissue sections were arranged serially on sets of 10 slides with 9 sections per
slide. Twenty to thirty slides were required to completely section the ascending
and abdominal regions of interest. To detect S100A4-Cre positive cells, one slide
from each series of 10 slides (9 sections/slide; 2-3 slides) was fixed in
paraformaldehyde (4%) for 10 min at 4oC, and stained for β-galactosidase using
X-gal protocol above. Then the sections were stained with eosin and
coverslipped. Blue stained cells were counted in all 9 sections per slide of each
mouse.
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AngII Induced Aneurysm induction
Male mice (8-10 weeks old) were fed a diet enriched in saturated fat
containing milk fat (21% wt/wt) and cholesterol (0.2% wt/wt) for 12 weeks (Diet#
TD.88137; Harlan Teklad; Indianapolis, IN). Male mice were used due to their
greater susceptibility to AngII-induced aneurysms formation. (160, 161) After 1
week of feeding, mini-osmotic pumps (Model #2004; Durect Corp; Cupertino, CA)
infusing either saline or AngII (1,000 ng/kg/min; Cat # H-1705; Bachem;
Torrance, CA) were implanted subcutaneously on the right flank of mice. (165)
The continuous infusion lasted 28 days.
Atherosclerosis induction
Male and female mice (8-10 weeks old) were fed the saturated fat
enriched diet listed above for 5 weeks.
Quantification of TAA, AAA, and atherosclerosis
Mice were terminated by an overdose of ketamine/xylazine mixture (90
mg, 10 mg/kg, respectively). After exsanguination via cardiac puncture, the right
atrium of the heart was cut to allow perfusate drainage. Then aortas were
perfused with saline, dissected free, and placed in 10% neutral buffered formalin
overnight. Twenty-four hours later, aortas were transferred to saline. Adventitia
was removed using a forceps and aortas were cut in half at the diaphragm.
Thoracic aortas were opened en face, pinned, and photographed.
Atherosclerosis was measured in accord with recent recommendations.
Abdominal aortas were pinned and photographed. Abdominal aortic diameter,
ascending aortic area, and atherosclerotic lesion area were measured using
ImagePro Plus software (Media Cybernetics, Inc.; Bethesda, MD) (166) (17, 167)
Statistics
Appropriate statistical analyses were based on numbers of groups
compared and parametric characteristics of the data using SigmaPlot (Systat
Software Inc.; San Jose, CA). Data are represented as mean ± SEM. P<0.05
was considered statistically significant.
5.4

Results

S100A4-Cre traced cells are abundant in fibroblast rich tissue and are increased
in aortas of AngII infused mice.
We demonstrated that S100A4-Cre is active in fibroblast rich tissues but
absent in fibroblast poor tissues. (Figure 5.1) However, both the thoracic and
abdominal aortas of S100A4-Cre+/0 x ROSA26-LacZ mice were not uniformly
positive. Histologic sections of both ascending and abdominal aortas
demonstrated scant positively traced cells in mice infused with saline. However,
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this population expanded after AngII infusion. An increased number of βgalactosidase-positive cells after AngII infusion were found in both aortic
segments
AT1a Receptor Excision by S100A4-Cre Significantly Attenuated AngII-induced
Thoracic and Abdominal Aortic Aneurysms But Did Not Protect Against AngIIinduced Atherosclerosis
Aortic rupture occurred in 5/28 Cre 0/0 and 5/32 Cre+/0 mice within 5 to
22 days of AngII infusion. There were no deaths in saline-infused mice of either
genotype. Location of aortic rupture was mixed; there were 3 thoracic and 2
abdominal aortic ruptures in both groups. As expected, AngII infusion
significantly increased aortic arch area compared to saline-infused mice in both
genotypes (P<0.001). However, the S100A4-Cre +/0 genotype had a significant
reduction in AngII-induced aortic arch dilation compared to 0/0 mice (P=0.003;
Figure 5.2). AngII infusion also significantly increased abdominal aortic diameter
compared to saline-infused mice in both genotypes (P<0.001). There was a
modest but significant decrease of abdominal aortic diameter in Cre +/0 mice
compared to 0/0 mice (P=0.029) AngII-induced atherosclerotic lesion area was
also measured in the arch (Figure 5.2). Saline-infused mice fed a fat-enriched
diet for 5 weeks had barely detectable atherosclerotic lesions; while AngII
infusion significantly increased atherosclerotic lesion area (P<0.001).
Atherosclerotic lesion areas were not different between genotypes.
AT1a Receptor Excision by S100A4-Cre Did Not Protect Against TAA in
Fbn1C1041G/+ mice
Male and female Fbn1C1041G/+ mice with fibroblast specific deletion of
AT1aR were generated. Mice were subject to ultrasound to measure both the
aortic root and ascending aorta. (Figure 5.3) Both male and female Fbn1C1041G/+
mice exhibited significant aortic dilation at 6 months of age. However, fibroblast
specific deletion of AT1aR failed to attenuate dilation in either segment.
5.5

Discussion
Our studies revealed seemingly disparate paradoxes about the role of
AT1aR on fibroblasts. S100A4-Cre mediated excision of the AT1a receptor
significantly attenuated AngII induced thoracic and abdominal aneurysm
formation but not TAA in Fbn1C1041G/+ mice. This occurred despite lifelong
deficiency of AT1aR in fibroblasts. The divergent role of AT1aR in spontaneous
versus syndromic aneurysms merits investigation. Additionally, rupture incidence
was not altered in these studies. Further studies may focus on the differences
between aortic dilation and aortic rupture as well as the mechanisms behind how
dilation may progress to rupture. Additionally, we have now systematically
demonstrated that excision of AT1a receptor within the aortic intima, media, or
adventitia fails to attenuate either AngII induced atherosclerosis despite whole
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body AT1a receptor being necessary for atherosclerosis formation. Despite the
majority of aneurysmal pathology and tissue remodeling affecting the smooth
muscle cell rich aortic media, we have now shown that Tie2 and S100A4-Cre
mediated depletion of AT1a receptors in endothelial cells and fibroblasts can
attenuate aneurysm formation whereas SM22-Cre mediated depletion cannot.
Thus, AT1aR dependent aortopathies rely on activation of AT1a receptors in
different cell types.
Surprisingly, cross-sections revealed that most β-galactosidase positive
cells were located in the media rather than the adventitial region of the aorta in
both saline and AngII-infused mice. The S100A4 promoter may encompass
fibroblasts actively remodeling in disease rather than quiescent fibroblasts in the
aorta. The S100A4 promoter was identified by comparative transcript analysis of
fibroblasts from different micro environments and other cell types and termed
fibroblast specific protein-1 (FSP1). (168) Recently, its specificity has been
questioned. Kong et al demonstrated that FSP1+ cells increased during
myocardial infarction, and >30% of these cells were identified as hematopoietic
or endothelial cells. (169) Rather than a marker for fibroblasts, FSP1 may be a
driver of fibrosis itself and deletion of AT1a receptor in actively remodeling
tissues -- rather than resident adventitial fibroblasts -- may be responsible for
protection against thoracic and abdominal aortic aneurysms. While we have
previously demonstrated S100A4-Cre mediated AT1a receptor deletion reduced
AT1a receptor mRNA, detection of AT1a receptor protein levels at this time has
been hampered by lack of specific AT1a receptor antibodies. This may also
signify that protection afforded by S100A4-Cre mediated AT1a receptor deletion
corresponds to the degree of AT1a receptor depletion within the whole aorta
rather than a cell-specific effect.
Future experiments should address alternate hypotheses and sites of
AT1aR action in aortopathies. Equally interesting may be the source of renin
angiotensin components, and whether components such as renin and
angiotensinogen derive from aortic tissue or from major body sources such as
the juxtaglomerular cells or liver respectively. Disparate cell types within the aorta
may have synergistic action through the AT1aR via autocrine/paracrine signaling.
Additionally, activation of extra-aortic AT1a receptors seems necessary for
atherosclerosis formation while activation of vascular AT1a receptors contributes
to aneurysm formation. In both cases, more research is needed to address the
exact cell types and signaling networks responsible for both atherosclerosis and
aneurysm formation. Future experiments in aneurysm formation should address
the crosstalk between endothelial and adventitial AT1a receptor activation and
medial aortic remodeling. Future experiments investigating the role of renin
angiotensin signaling in atherosclerosis should focus on AngII-responsive extraaortic tissues and organs such as the brain and kidney.
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Figure 5.1 S100A4-Cre traced cells were preferentially enriched in fibroblast
rich tissues
β-galactosidase activity (depicted by blue color) by S100A4-Cre mediated
excision of ROSA26 in selected whole organs from S100A4-Cre 0/0 x Rosa26LacZ (left side of each panel) and S100A4-Cre +/0 x Rosa26-LacZ (right side of
each panel) in A) fibroblast-rich tissue B) non-fibrotic tissue and the C) thoracic
and abdominal aortas. Cre transgene is identified as +/0. D) Representative
sections from series of ascending and abdominal aortas from S100A4-Cre x
ROSA26-LacZ mice infused with saline. Stained with β-galactosidase activity and
imaged at 200x magnification. AngII infusion changed distribution of lineage
traced cells in the ascending and abdominal aortas.
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Figure 5.2 AT1a receptor deletion attenuated AngII-induced TAA and AAA
but not AngII-exacerbated atherosclerosis
Representative images of A) enface ascending aortas and B) ex vivo
aortas from fibroblast specific AT1aR deficient x LDL receptor -/- mice infused
with either saline or AngII. S100A4-Cre mediated excision of AT1a receptors
reduced aortic dilation in C) ascending D) and abdominal aortas of AngII-infused
male LDL receptor -/- mice, but had no effect on E) AngII-augmented
atherosclerosis despite reductions in F) total plasma cholesterol. For C): *
denotes P<0.001 comparing saline versus AngII within genotypes by HolmSidak. # denotes P=0.007 comparing AngII infused 0/0 versus +/0 by HolmSidak. For D): * denotes P<0.001 when comparing infusions within 0/0 genotype
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by Holm-Sidak. # denotes P=0.029 comparing AngII infused 0/0 vs +/0 by
Student’s t-test. For E) * denotes P<0.001 for saline versus AngII infusion within
Cre 0/0 and +/0 by Holm-Sidak. For F) # denotes P<0.05 comparing AngII
infused 0/0 vs +/0
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Figure 5.3 Fibroblast specific AT1aR deletion failed to modulate TAA in
Fbn1C1041G/+ mice
Representative ultrasound images in A) male and D) female mice with
fibroblast specific deletion of AT1aR. S100A4-Cre driven deletion failed to
attenuate B,E) aortic root and C, F) ascending aortic dilation. * p<0.05 when
comparing Fbn1+/+ vs. Fbn1C1041G/+.
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CHAPTER 6. DISCUSSION AND FUTURE DIRECTIONS
The overarching goal of these projects was to elucidate factors that were
responsible for and can modulate development of Marfan syndrome associated
thoracic aortic aneurysms. In accomplishing this goal, we not only developed and
validated new methods but also defined the contributions of the AngII-AT1aR
axis, sex hormones, and AT1aR on fibroblast to pathogenesis.
6.1

Key Methods

To trace the development of TAA sequentially, we needed a non-invasive,
in-vivo method of assessing the ascending aorta over the course of the study.
We utilized high frequency ultrasound as it had key advantages over other
techniques of assessing the ascending aorta. Overall, strengths of ultrasound
include low cost and rapid data acquisition compared to more resource intensive
imaging modalities such as computed tomography (CT) and magnetic resonance
imaging that have been used in studies of aortopathies. (134, 137, 170, 171) No
contrast agent is needed for imaging small vessels and imaging data can be
acquired much more rapidly with less resources. Additionally, data analysis for
three-dimensional (3D) computed tomography and magnetic resonance imaging
modalities is much more labor intensive. Despite these advantages, ultrasound
has key limitations. Accurately imaging and measuring eccentric aortic dilation is
difficult in two-dimensional (2D) ultrasonography. In fact, techniques such as
phase contrast X-ray tomographic microscopy and contrast enhanced micro-CT
have been proposed as a gold standard for 3D imaging of murine aortas because
they are able to detect eccentric dilation. The trans-thoracic ultrasound
acquisition and analysis protocol used in this study operates under the
assumption that the maximum point of the aorta is imaged and that the aorta
expands concentrically with the cardiac cycle. In the aneurysmal state, the
dilation is eccentric. In fact, ulceration, dilation, and rupture preferentially occur
along the greater curvature. (17) The point of greatest dilation may not occur
perpendicular to the aortic valves and innominate artery where this study
measures the ascending aorta. Therefore, 3D modalities are useful to elucidate
small effect sizes while less accurate 2D methods may be sufficient if effects
sizes are large. Advent of 3D ultrasound reconstruction may play a key role by
utilizing the advantages of both techniques by decreasing acquisition times. In
the lieu of 3D imaging modalities, ex vivo measurements may be valuable in
illustrating aortic eccentricity in mice but is not feasible in longitudinal studies.
While we did not assess if non-invasive 3D imaging modalities are indeed
superior or more accurate, those interested in performing aortic imaging studies
should balance the resource requirements against the desired accuracy and
precision of the data.
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To overcome the limitations of ultrasound, we additionally performed aortic
histology to determine if our interventions directly impacted the ascending aorta.
This allowed direct measurement of changes to the structure of aortic tissue but
are also subject to limitations. We observed that aortas from Marfan syndrome
mice exhibit extensive elastin fragmentation and fibrosis, suggesting a loss of
elasticity and increase in stiffness. (12, 124) This is consistent with observations
made in aneurysmal tissue from AngII-induced TAAs. (37) However, key
limitations of histologic assessment of the aorta include the section of aorta
measured and the subjective nature of measurement. The American Heart
Association recommends that aortopathy studies keep consistent the region of
aorta analyzed within a study. (33) As we measured aortic dilation at the area of
maximal expansion, this means that histologic sections should be taken at area
of maximal expansion as well. This is logistically difficult. While care was taken to
quantify elastin fragmentation in the aortic section of largest dilation, aortic
sections still are a two-dimensional representation of a tortuous threedimensional structure. Additionally, assessment of elastin fragmentation and
degree of staining was performed by human observers blinded to group
assignment. While randomization and blinding reduce bias, use of human
observers reduce both the resolution and throughput of measurements. Indeed, it
is possible to train an agnostic computer program or artificial intelligence program
to perform any measurement of image data in an unbiased manner. However,
this would require not only development and deployment of this resource but also
training data. Because of the small sample sizes and raw data, it would be
difficult to generate both a training and test set of data. By including raw data
available in our publications, we may enable future researchers to use our data
as a training set for their experiments. Ultimately, these measurements do not
stand alone but rather complement measurements from other modalities; we are
confident in our observations due to the correlation and agreement of multiple
modalities for measuring TAA severity.
6.2

Role of AngII-AT1aR axis in Marfan syndrome

We determined that inhibition of the AngII-AT1aR axis, by either
pharmacologic depletion of the unique precursor of angiotensin ligands or
genetic deletion of the main AT1 isoform in the aorta, attenuated TAA in the male
Fbn1C1041G/+ mice. Previous studies claimed that the protective effects of losartan
in TAA stem from its pleiotropic or non-AT1aR dependent effects. Sellers et al
claimed that losartan, an AT1aR blocker, had divergent effects on Marfan
syndrome associated TAA compared to AT1aR deletion. (86) Specifically,
losartan attenuated TAA through preservation of endothelial function in an
AT1aR independent manner through an alternative VEGFR2/eNOS pathway.
Other studies suggested that losartan’s protective effect may be due to tumor
growth factor β inhibition or AngII receptor type 2 hyperstimulation. (64, 83)
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However, our data indicated that blockade of the AngII-AT1aR axis is sufficient to
attenuate Marfan syndrome associated TAA. Consistent with our observations, a
recently published study in the severe Fbn1mgR/mgR model indicated that deletion
of endothelial AT1aR reduced death by TAA rupture.(75)
Additionally, the contribution of angiotensin receptor ligands was unclear.
Neither ACE inhibitors nor angiotensinogen knockout were efficacious in
attenuating dilated cardiomyopathy in the Fbn1mgR/mgR mouse model.(74)
Unfortunately, use of either modality in aortopathy research is difficult due to
pleotropic effects of ACE inhibitors on the kinin-kallikren system and cardio-renal
developmental defects of AGT knockout.(155) Therefore, we used a systemic,
post-natal inhibition of AGT synthesis via AGT ASO to deplete AGT.(149) This
resulted in sustained AGT depletion and corresponded to reduction in Marfan
syndrome associated TAA in male mice. We concluded that angiotensin receptor
ligands are critical in TAA and that depletion of AGT is sufficient to attenuate
Marfan syndrome associated TAA. These findings expanded previous
understanding of the role of the renin angiotensin system in Marfan syndrome
associated TAA and challenged the previous paradigm that non-AT1aR effects
modulated TAA. While we do not discount the pleotropic effects of losartan and
its metabolites, inhibition of AngII dependent AT1aR stimulation may be a key
component in attenuating TAA.
However, the direct link between fibrillin-1 and the renin angiotensin
system is not clear. It is unexpected that mutations in an extracellular matrix
protein would impact the production of ligands responsible for blood pressure
control. Angiotensin ligands are mainly synthesized in the liver, an organ not
known to have abundant connective tissue. Thus fibrillin-1 may either act on local
synthesis of angiotensin peptides or act on extra-aortic tissues in a yet undefined
manner. To establish causal links between these two components, future studies
should leverage inducible mutations of fibrillin-1 to trace progressive
dysregulation of both the aortic and systemic renin angiotensin system.
6.3

Role of endogenous sex hormones in aortopathy

We demonstrated that removal of endogenous sex hormones was able to
modulate spontaneous TAA. The AngII infusion mouse model induces thoracic
aortic aneurysms in normolipidemic conditions and independent of blood
pressure changes. (28, 37) Thoracic aortic aneurysms in AngII induced mice
impact the ascending aorta more than the aortic root. While TAAs are
characterized as a disease that preferentially impacts the aortic root, our group
and others have demonstrated that TAA mouse models also involved the
ascending aorta - defined as the segment proximal to the innominant artery. (31,
51, 64) Interestingly, gonadectomies did not affect lengthening of the ascending
aorta in AngII infused mice, pointing to marked anisontropy of the ascending
aorta. Indeed, this observation is consistent with those in abdominal aortic
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aneurysms between male and female mice. Previous work in LDL receptor-/- x
AngII-induced abdominal aortic aneurysms (AAAs) revealed that having a female
sex chromosome complement and exposure to endogenous female sex hormone
attenuates initiation, progression, and extent of AAAs. (160, 161, 172)
Conversely, our data suggests that removal of endogenous sex hormones
was unable to modulate established TAA in Fbn1mgR/mgR mice. The FBN1mgR/mgR
mice exhibit rapid dilation and death by aortic rupture early in life. Indeed, by 56
days old – when our gonadectomy studies were initiated, approximately 10% of
male FBN1mgR/mgR mice would have expired due to TAA rupture. This mortality
makes working with FBN1mgR/mgR mice difficult as interventions would need to
have dramatic effect to alleviate already present aortic dilation. Thus, the effect of
gonadectomy in modulating TAA in FBN1mgR/mgR mice may be masked by both
existing TAA and mortality due to TAA rupture. Future experiments should
investigate the effect of gonadectomy in the milder FBN1 C1041G/+ or GT8/+
models that do not have marked mortality to allow measurement over a longer
course.(11, 52) Before we can make the conclusion that gonadectomy is
ineffective in syndromic TAA, we must first establish if it acts on the initiation or
progression of TAA.
6.4

Role of AT1aR on fibroblasts in aortopathy

S100A4-Cre mediated deletion of AT1aR on fibroblasts had divergent
effects on AngII-induced TAA versus Fbn1C1041G/+ mediated TAA. While we have
discussed the limitations of using S100a4-Cre as a fibroblast specific Cre, the
divergent effects on spontaneous and syndromic aortopathies merit discussion.
The mechanism by which this occurs is unclear. All components necessary for
the deletion of AT1aR were present in germ line cells. However, we make the
assumption that deletion of AT1aR was equivalent between C57BL/6J mice and
Fbn1C1041G/+ mice. This may not be true as AngII infusion increases S100A4-Cre
traced cells in the aortic media. On future experiment that would allow us to
interpret these results would be to lineage trace S100A4-Cre positive cells in the
Fbn1C1041G/+ mice in a lineage tracing experiment.
Initially, the obvious hypothesis was that AT1aR on cells of the aortic wall
were responsible for aortopathy. In conjunction with other published studies,
AT1aR deletion on all major cell types in the aorta have been performed.
Endothelial specific AT1aR deletion has marginal effect on TAA. Smooth muscle
specific AT1aR has no effect. Fibroblast specific deletion has partial effect on
AngII induced aortopathies and no effect of syndromic TAA. Thus, the cell type
where AT1aR is stimulated is still unknown. Altogether, there are two alternate
hypotheses. First, it is possible that extra-aortic AT1aR is responsible for
aortopathies. Indeed, promising results show that renal specific AT1aR deletion
modulates atherosclerosis through yet undefined means. Additionally, the base
assumption that a single cell type is responsible for TAA becomes increasingly
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untenable. While breeding multiple cell lineage specific deletions in a single
animal requires novel mouse models and heroic efforts, new targeted gene
editing technologies and pharmacologic agents may allow a combination of cell
specific knockdowns. For example, it is now possible to target antisense
oligonucleotides to both the liver and the kidney independently. The responsible
cell(s) type for TAA will eventually be discovered.
6.5

Future directions

Several avenues of promising research stem from the studies outlined here.
The overarching goals should remain increasing understanding of and
developing therapies for Marfan syndrome associated TAA.
It is unclear whether the contribution of disparate systems, such as the
renin angiotensin system and endogenous sex hormones, to Marfan syndrome
associated TAA occur in isolation or have cross talk. The renin angiotensin
system effects some functions through regulation of aldosterone, a
minerocorticoid hormone. While its main function is to regulate salt and water
balance as well as blood pressure, pleiotropic effects on endogenous sex
hormones is less well known. Conversely, it is known that circulating sex
hormone levels regulate liver protein synthesis. As angiotensinogen in the
plasma is mainly synthesized by the liver, it is unknown if gonadectomy alters the
renin angiotensin system in a manner that would affect aortopathies. Finally, as
both the renin angiotensin system and sex hormones have many downstream
effectors, it is unclear where these pathways intersect. Future studies may
leverage unbiased multi-omics to uncover these interaction networks. The goal of
those studies should focus on common up or downstream regulators that can be
pharmacologically targeted.
Future mouse studies should also aim to resolve controversy and
divergent effects seen between spontaneous and syndromic TAA. Differences
may stem from differences in the timing of initiating events. The aorta develops
between embryonic day 14 and postnatal day 21. Many spontaneous TAAs rely
on an investigator-initiated administration of a causative agent. This usually
occurs much later, at around 8 weeks of age. Absent a vascular insult, the aortas
from baseline mice can be considered normal and non-aneurysmal. Indeed, it is
rare for C57BL/6J mice to spontaneously develop TAA even at advanced ages.
In contrast, syndromic models rely on a germline mutation, and thus the initiating
event occurs in utero. The consequences of difference in timing may underly the
divergent effects of gonadectomy as this is after sexual maturity. Therefore,
inducible models of syndromic TAA, using an inducible Cre-Lox system to mutate
or delete causative genes such as Fbn1, can be used to control the timing of the
vascular insult. Conversely, it may be possible for investigators to initiate
administration of TAA causing agents earlier.
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It is critical to test observations and paradigms elucidated in mouse
studies in a human population. Observations to be tested include the role of the
AngII-AT1aR axis on Marfan syndrome associated TAA and the effects of sex on
spontaneous and syndromic TAA. We may leverage clinical data by performing a
retrospective observational study looking at the association of either
pharmacologic agents or sex and TAA and aortic dissection. To study if TAA is
also modulated by AT1aR in a ligand dependent manner, we can test the
association between ACE inhibitors, ARBs, and aortic phenotypes. To study if
sex hormones modulate TAA, we may look at the incidence of TAA and
dissection in pre- versus post- menopausal females, males and females currently
receiving hormone therapy, or males and females who have received surgical
oophorectomy or orchiectomy. However, the populations of these patients may
be small thus these studies would have difficulty achieving power. Unfortunately,
it is difficult to perform lineage tracing and developmental biology experiments in
humans. However, primary cell lines or induced pluripotent stem cells may be
leveraged to test AT1aR dependent signaling pathways in humans. Ultimately,
the cell type to be tested would depend on the cell type elucidated in mouse
studies. Thus, the studies outlined here as well as future studies can be
leveraged to generate hypotheses to be tested in humans.
Development of an effective pharmacologic agent hinges on the
demonstrating superiority to current standard of care. However, current standard
of care varies between institutions and providers. Patients with Marfan syndrome
are generally treated with beta-adrenocorticoreceptor blockers and angiotensin
receptor blockers. However, evidence for the efficacy of either agent is lacking.
Evidence for use of beta-adrenocorticoreceptor blockers is based on one
underpowered study that had strong predisposition to bias. (59) Evidence for use
of angiotensin receptor blockers is mixed, with several studies of losartan
showing minimal effect. (58) The widespread use of either agent means that any
new agents would be trialed as an add-on agent to standard of care. Promising
agents include AGT-ASOs and – if demonstrated in future experiments – agents
that modulate estrogens or androgens or their targets in the aorta.
Ultimately, these avenues of research should be performed concurrently
and in an iterative manner. Novel observations in mouse studies can be
confirmed in retrospective human data and further refined by developing more
specific and targeted pharmacologic agents. Associations seen in humans
studies can be tested in the optimized environment using validated mouse
models to discover their mechanism of action. Granting agencies and
foundations should champion research programs in both areas concurrently.
Trainees and faculty should aim to collaborate across disciplines if not receive
training in interdisciplinary techniques themselves. Momentum behind this
research is building. Marfan syndrome was first described in 1896. The gene
responsible, FBN1, was discovered in 1995. The first promising agent in mice
and humans was described in 2006. Throughout this timeline, life expectancy in
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patients living with Marfan syndrome has increased. It is hoped that the studies
outline here provide a platform to continue this momentum.
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